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ABSTRACT 
 In MODY3 patients, as well in the experimental mouse model, the Tcf1 -/- 
mouse, there is a defect in arginine-induced insulin secretion.  In this thesis, we 
examined the role of arginine transporters in the insulin secreting cells in 
arginine-induced insulin secretion.  We first characterized arginine uptake by 
MIN6 cells as having a Km of 102.6μM and being partially Na-dependent and 
entirely Cl-dependent.  We then examined Tcf1 -/- pancreatic islets, which are 
defective for arginine-induced insulin secretion.  Using gene expression array 
analysis and semi-quantitative RT-PCR analysis on pancreatic islets from Tcf1 
+/+ and Tcf1 -/- mice, we found eight arginine transporters expressed in the 
pancreatic islets with only two transporters, mNAT3 and CAT3, regulated by 
Tcf1 in the islets.  Using siRNA-mediated knockdown of both transporters, we 
found that these transporters are not required for arginine-induced insulin 
secretion in MIN6 cells.  We conclude that there is a high level of redundancy for 
arginine transport into insulin-secreting cells.   
 We also examined the regulation of mNAT3 in the liver.  The liver is the 
main site for gluconeogenesis during fasting, and has been shown to increase 
amino acid uptake during periods of low nutrient intake to increase its substrate 
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pool for glucose production.  We found that mNAT3 is upregulated during 
fasting, and that this response is abolished with insulin.  Using mice injected 
with adenovirus expressing either Foxa2 or GFP as a control, we found that 
Foxa2 mediates this insulin-sensitive increase in hepatic mNAT3 expression.  
Through electrophoretic mobility shift assays and chromatin immuno-
precipitation experiments, we found that Foxa2 binds to promoter elements of 
the mNAT3 gene, Slc38a4.  We also showed these promoter elements to be 
important for Foxa2 transactivation using luciferase reporter gene assays.  In 
addition, with liver perfusion experiments using mice infected with adenovirus, 
we found increased arginine uptake by livers overexpressing Foxa2.  Thus, we 
have identified Foxa2 as a mediator for increased hepatic amino acid uptake 





 I am deeply indebted to my mentor, Markus Stoffel.  My years in his 
laboratory have been ones where I have learned the most about science and 
medicine, as well as the practice of both.  It has been a privilege to work with 
someone whose genuine enthusiasm for science and the application of it I very 
much admire.   
 I am also grateful that he has such excellent taste in selecting his lab 
members.  The Stoffel Lab has always been a wonderful place to work with 
wonderful people.  I am thankful to Satoru Kuwajima, David Shih, and Christian 
Wolfrum for being there when I first joined the lab, welcoming me and enduring 
my many, many questions.  I am particularly thankful to Pinar Akpinar, for 
being the greatest bay-mate over all these years.  And a big thanks to the entire 
lab with whom I have enjoyed many laughs about jelly doughnuts. 
 My happiness throughout these years also would not have been possible 
without my MD-PhD classmates.  From our first meeting in 1999, they have all 
been the most supportive and brilliant group of people I have ever had the 
pleasure of being thrown together with.  I look forward to many more years 
together (though hopefully not so many as students).   
 I owe everything to my parents, Lou-Chuang and Li-her Lee, and my 
sister, Jane, for I cannot even imagine where I would be right now if it were not 
for their love, support, and inspiration by example, which I have enjoyed all my 
life.  I would also like to thank Matteo Ruggiu, the consummate scientist, for 
being a constant reminder of all things great in my life.   
 
vi 
TABLE OF CONTENTS 
 Page 
CHAPTER 1 – INTRODUCTION TO ISLET STUDIES....................................... 1 
1.1  Introduction .......................................................................................................... 1 
1.2  Diabetes Mellitus .................................................................................................. 2 
1.3  Maturity-onset diabetes of the young (MODY)................................................... 4 
1.4  MODY3 and TCF1............................................................................................... 6 
1.5  Insulin secretion mechanisms ............................................................................... 7 
1.6  Insulin secretion defects in the Tcf1 -/- pancreatic islets...................................... 12 
1.7  Arginine transporters ........................................................................................... 12 
1.8  Experimental study............................................................................................... 16 
  
CHAPTER 2 – RESULTS PART I ............................................................................ 18 
2.1  Characterization of arginine uptake by MIN6 cells ............................................. 18 
 2.1.1  Timecourse of arginine uptake by MIN6 cells ............................................. 18 
 2.1.2  Dose-dependence of arginine uptake by MIN6 cells.................................... 19 
 2.1.3  Kinetics of arginine uptake by MIN6 cells .................................................. 20 
 2.1.4  Effect of ion substitution on arginine uptake by MIN6 cells ...................... 21 
2.2  Gene expression array analysis of Tcf1 +/+ and Tcf1 -/- pancreatic islets........... 22 
2.3  Characterization of arginine transport by Slc38a4 .............................................. 24 
 2.3.1  Timecourse of arginine transport by mNAT3 ............................................. 24 
 2.3.2  Dose-dependence of arginine transport by mNAT3 .................................... 25 
 2.3.3  Kinetics of arginine transport by mNAT3 .................................................. 26 
 2.3.4  Effect of ion substitution on arginine transport by mNAT3....................... 27 
2.4  Tissue expression of arginine transporters ........................................................... 28 
2.5  Arginine transporter expression in Tcf1 +/+ and -/- pancreatic islets ................ 29 




 2.6.1  Knockdown of Slc38a4 (mNAT3) in MIN6 cells ........................................ 31 
 2.6.2  Knockdown of Slc7a3 (CAT3) in MIN6 cells.............................................. 33 
 2.6.3  Knockdown of both Slc38a4 (mNAT3) and Slc7a3 (CAT3) ....................... 35 
  
CHAPTER 3 – DISCUSSION PART I..................................................................... 36 
3.1  Characterization of arginine uptake by insulin-secreting cells ............................ 36 
3.2  Implications for arginine-induced insulin secretion in Tcf1 -/- mice................... 38 




CHAPTER 4 – INTRODUCTION TO LIVER STUDIES...................................... 42 
4.1  Overview of insulin action ................................................................................... 42 
4.2  Insulin receptor and insulin receptor substrates .................................................. 44 
4.3  Insulin-regulated signaling pathways .................................................................. 46 
4.4  Transcription factors involved in insulin-regulated hepatic metabolism............. 49 
4.5  Forkhead family of transcription factors............................................................... 51 
4.6  Insulin signaling and amino acid uptake ............................................................. 54 
4.7  Experimental study............................................................................................... 55 
  
CHAPTER 5 – RESULTS PART II........................................................................... 56 
5.1  Tcf1 regulation of Slc38a4 in the pancreatic islets and the liver.......................... 56 
5.2  Alternative transcriptional start sites for Slc38a4 ............................................... 56 
5.3  Tcf1 regulation of both transcriptional isoforms of Slc38a4................................. 57 
5.4  Regulation of Slc38a4 in the liver by metabolic states and insulin...................... 58 
5.5  Slc38a4 is regulated by Foxa2 .............................................................................. 60 








5.8  Synergistic transactivation of Slc38a4 by Tcf1 and Foxa2 .................................. 70 
5.9  In vivo binding of Foxa2 to the Slc38a4 promoters .............................................. 71 





CHAPTER 6 – DISCUSSION PART II ................................................................... 74 
6.1  Alternative splicing as a mechanism for differential regulation of Slc38a4 ......... 74 
6.2  Regulation and function of Slc38a4 in the liver ................................................... 77 
  
CHAPTER 7 – EXPERIMENTAL PROCEDURES................................................ 80 
7.1  Experimental animals ........................................................................................... 80 
7.2  Cell culture ........................................................................................................... 80 
7.3  In vitro radioactive ligand uptake assay ............................................................... 80 
7.4  Pancreatic islet isolation ....................................................................................... 81 
7.5  Gene expression array analysis............................................................................. 82 
7.6  RNA interference .................................................................................................. 83 
7.7  Protein immunoblotting ....................................................................................... 84 
7.8  In vitro insulin secretion and measurement......................................................... 85 
7.9  Vectors .................................................................................................................. 85 
viii 
7.10  Transient transfections and luciferase assay ...................................................... 87 
7.11  Whole cell extract preparation for electrophoretic mobility shift assays ............ 87 
7.12  Electrophoretic mobility shift assay (EMSA) ..................................................... 88 
7.13  Chromatin immunoprecipitation ........................................................................ 89 





LIST OF FIGURES AND TABLES 
 
 Page 




Figure 1.  Schematic diagram of the insulin secretion pathway ........................ 11 




Figure 2.  Timecourse for arginine uptake by MIN6 cells................................... 19 
Figure 3.  Dose-dependent uptake of arginine by MIN6 cells............................ 20 
Figure 4.  Lineweaver-Burk plot for MIN6 arginine uptake............................... 21 
Figure 5.  Na- and Cl-dependence of arginine uptake by MIN6 cells............... 22 
Table 3.  Gene expression array results for arginine transporters in Tcf1 
+/+ and Tcf1 -/- pancreatic islets...........................................................................
 
24 








Figure 8.  Lineweaver-Burk plot fo mNAT3-mediated arginine transport ...... 27 
Figure 9.  Na- and Cl-dependence of mNAT3-mediated arginine uptake 
by COS-7 cells ............................................................................................................
 
28 
Figure 10.  Expressing of arginine transporters in various tissues .................... 29 
Figure 11.  Tcf1 regulation of arginine transporters in pancreatic islets........... 30 
Figure 12.  mNAT3 knockdown in MIN6 cells ..................................................... 31 
Figure 13.  Arginine uptake with mNAT3 knockdown in MIN6 cells.............. 32 
Figure 14.  Insulin secretion with mNAT3 knockdown in MIN6 cells ............. 33 
Figure 15.  Arginine uptake measurements in MIN6 cells electroporated 
with Slc7a3 siRNA ....................................................................................................
 
34 
Figure 16.  Insulin secretion with Slc7a3 knockdown in MIN6 cells................. 34 
Figure 17.  Knockdown of both Slc38a4 and Slc7a3 in MIN6 cells .................... 35 
Figure 18.  Tissue metabolism with low insulin................................................... 43 
Figure 19.  Main pathways of insulin signaling ................................................... 47 








Figure 22.  Slc38a4 has two distinct transcriptional start sites ........................... 57 
Figure 23.  Both transcriptional isoforms of Slc38a4 are regulated by Tcf1 ..... 58 
x 




Figure 25.  Slc38a4 regulation by Foxa2................................................................. 61 




Figure 27.  Mutation of the Tcf1/Foxa2 site leads to decreased 





Figure 28.  EMSA using oligonucleotides for the putative Tcf1/Foxa2 
binding site in the Slc38a4 “islet” promoter..........................................................
 
65 




Figure 30.  Mutation of the Tcf1 and Foxa2 sites leads to decreased 





Figure 31.  EMSA using oligonucleotides for the putative Tcf1 and Foxa2 
binding sites in the Slc38a4 “liver” promoter .......................................................
 
69 
Figure 32.  Tcf1 and Foxa2 act synergistically to transactivate through the 
Slc38a4 “islet” and “liver” isoform promoters .....................................................
 
71 
Figure 33.  Foxa2 binds to the Slc38a4 promoters in vivo................................... 72 







INTRODUCTION TO ISLET STUDIES 
 
1.1  Introduction 
 Insulin is a polypeptide hormone that coordinates energy fuel metabolism 
and generation in different tissues of the body.  It is produced by the beta-cells of 
the islets of Langerhans, which are clusters of cells that make up 1% of the 
pancreas.  Insulin is secreted by the beta-cells in response to increases in blood 
glucose, certain amino acids, and fatty acid levels.  Thus, insulin secretion is a 
marker for the “fed” state; accordingly, its metabolic effects are anabolic, leading 
to synthesis of glycogen from glucose, triacylglycerols from fatty acids, and 
protein from amino acids.  In a “fasted” state, insulin levels are low in the body.  
The body responds by maintaining glucose levels through glycogen breakdown 
and gluconeogenesis, as well as by generating ketone bodies through lipolysis 
and fatty acid oxidation, in order to maintain a steady source of energy for all the 
tissues in the body.   
 In this thesis, we examined the relationship between insulin and amino 
acid transport.  As described before, amino acids stimulate the secretion of 
insulin.  In fact, before the oral glucose tolerance test, insulin secretion defects 
were formerly diagnosed in the clinic by a test where a bolus of arginine was 
administered and the resulting levels of insulin in the blood were measured.  
Despite the fact that arginine-induced insulin secretion has been long-established 
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and used as a diagnostic tool in the clinic, little is known about the mechanism 
and the molecules involved.  We endeavored to identify genes that may be 
involved in arginine-stimulated insulin secretion to gain a better understanding 
of the insulin secretion process.  Given the current global epidemic of type 2 
diabetes, which is characterized by insulin resistance and/or abnormal insulin 
secretion, we were interested to learn about alternative pathways leading to 
insulin secretion, in hopes that they may either shed light on the pathogenesis of 
diabetes or be manipulated for therapeutic purposes.   
 We also looked at the relationship of insulin signaling and amino acid 
transport in the liver in our study.  As described before, when the body is in a 
“fasted” state, insulin levels are low.  This triggers the body to increase glucose 
production, either through glycogen breakdown or by gluconeogenesis.  The 
liver is the site of 90% of gluconeogenesis in the body.  Amino acids are used as 
substrates for gluconeogenesis.  Thus, to address the increase in amino acid 
consumption for gluconeogenesis, the liver needs to increase the uptake of amino 
acids during periods of fasting.  The molecular mechanisms linking insulin 
action to hepatic amino acid transport were examined in this thesis, and are 
described later in Chapters 4 through 6. 
 
1.2  Diabetes mellitus 
 Diabetes is an endocrine disorder in which there is a deficiency in insulin 
action.  There are two main forms of diabetes: type 1 diabetes is characterized by 
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an absolute insulin deficiency due primarily to an autoimmune-mediated 
destruction of pancreatic beta-cells, while type 2 diabetes, which comprises about 
90% of diabetes cases, is characterized by insulin resistance and/or abnormal 
insulin secretion (Zimmet et al., 2001).  The number of people worldwide with 
either type of diabetes was estimated at 150 million in 2001.  The number of affect 
people was also predicted to increase to 220 million in 2010 and 300 million in 
2025.  The increase in the prevalence of diabetes is mostly due to an epidemic of 
type 2 diabetes, which is strongly associated with a sedentary lifestyle and 
obesity (Zimmet, 1999).  Sharp rises in the incidence of type 2 diabetes have been 
observed in both developed and developing countries (Zimmet, 1999).   
 People with diabetes are susceptible to a variety of complications that 
cause morbidity and premature death, including accelerated atherosclerosis, 
retinopathy, nephropathy, neuropathy, and foot ulcers.  In fact, diabetic 
retinopathy is the leading cause of blindness in the United States; in addition, 
diabetic nephropathy is the leading cause of end-stage renal disease in the U.S.  
Because of the morbidity and mortality associated with diabetes, a lot of focus 
has been placed prevention of complications.  In a study performed by the 
Diabetes Control and Complications Trial Research Group in 1993, it was 
established that intensive control of blood glucose levels was useful in the 
prevention of the retinopathy, neuropathy, and nephropathy associated with 
diabetes. 
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 In addition to the treatment of diabetes, much attention has also been 
placed on the prevention of diabetes.  Many studies have been directed at 
identifying people who are at an increased risk of developing type 2 diabetes.  
Most of these studies have focused on individuals with impaired glucose 
tolerance (IGT).  Subjects are given an oral glucose load, and blood glucose levels 
are determined two hours following the glucose administration.  Individuals 
with IGT have blood glucose levels intermediate between normal and diabetic 
individuals.  In addition, people with increased fasting glucose levels have also 
been shown to have a greater risk of developing type 2 diabetes.   
 
1.3  Maturity-onset diabetes of the young (MODY) 
 The understanding of the progression of diabetes also requires an 
understanding of the mechanisms that control insulin secretion and mediate 
insulin actions.  In the study of insulin secretion, animal model systems become 
especially important since it is difficult to take pancreatic islet biopsies from 
patients to study insulin secretion.  In order to understand the changes that occur 
in diabetes, diabetic animal models are also important for comparison.  Type 2 
diabetes is generally a multifactorial disease, associated with ethnicity and 
gender, as well as advanced age, making it difficult to model in an animal system 
(Groop, 1997).  However, there also exists a form of diabetes that is caused by 
mutations in a single gene, called maturity-onset diabetes of the young (MODY).  
Since diabetes is caused by a single gene mutation in MODY, the MODY genes 
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have been used as targets for genetic mouse manipulations to generate animal 
models of diabetes. 
MODY accounts for 1-2% of all diabetes cases, and is characterized by 
development of diabetes early in life (often before the age of 25) and autosomal 
dominant inheritance.  So far, six genes have been identified, which lead to 
MODY when mutated (Table 1): hepatocyte nuclear factor 1α (HNF1α, TCF1), 
hepatocyte nuclear factor 1β (HNF1β, TCF2), hepatocyte nuclear factor 4 (HNF4), 
pancreatic and duodenal homeobox gene 1 (PDX1), neuroD1, and glucokinase 
(Frayling et al., 2001; Fajans et al., 2001).  The glucokinase gene encodes an 
enzyme that catalyzes the first step in glycolysis, which is essential for generating 
the metabolic signal to stimulate insulin secretion in response to glucose 
(Matchinsky, 2000).  All of the other MODY genes encode transcription factors 
that are important in multiple metabolic pathways (Shih and Stoffel, 2002).   
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Studies of the MODY genes and their function in animal models have 
uncovered many diverse processes that are essential for proper maintenance 
levels.  These processes range from mechanisms by which pancreatic beta-cells 
detect glucose, to neuroendocrine tissue development during embryogenesis, to 
beta-cell hyperplasia as an adaptive response to maintain normal glucose levels 
during physiological growth or in obesity (Matchinsky, 2005; Sander and 
German, 1997; Akpinar et al. 2005).   
1.4  MODY3 and TCF1 
 Maturity-onset diabetes of the young type 3 (MODY3) is the most 
common of all the MODYs, accounting for 70% of all MODY cases.  MODY3 is 
caused by mutations in the TCF1 gene.  TCF1 encodes a homeodomain 
transcription factor composed of an amino-terminal dimerization domain, a 
POU-homeobox DNA-binding domain, and a carboxy-terminal transactivation 
domain (Mendel and Crabtree, 1991).  Tcf1 is expressed in the liver, kidney, 
intestines, and pancreatic islets (Blumenfeld et al., 1991).  There is no defect in 
insulin action in MODY3 patients; thus, impaired beta-cell function appears to be 
the primary cause of diabetes in these patients (Fajans et al., 2001).  MODY3 
patients demonstrate a defect in glucose- and arginine-induced insulin secretion 
as well as hypersensitivity to sulfonylurea therapy.  In addition, MODY3 patients 
may also have glycosuria, resulting from decreased renal reabsorption of glucose 
(Menzel et al., 1998; Pontoglio et al., 2000).  Depending on glycemic control, these 
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patients may suffer the full spectrum of diabetic complications, including 
blindness and kidney failure (Fajans et al., 2001).   
Tcf1 has been genetically knocked out in mice (Pontoglio et al., 1996; Lee 
et al., 1998).  Unlike in humans, where a single defective Tcf1 allele leads to 
disease, the Tcf1 +/- mice have no detectable phenotype.  Tcf1 -/- mice have 
been shown to have a phenotype of defective glucose- and arginine-induced 
insulin secretion and hypersensitivity to sulfonylureas, as well as dwarfism, 
renal Fanconi-like syndrome, and defects in bile acid and plasma HDL-
cholesterol metabolism (Pontoglio et al., 1996; Lee et al., 1998; Pontoglio et al., 
1998; Shih et al., 2001).  When normalized to pancreatic weight, the insulin 
content of the Tcf1 -/- mice was 60% that of wild-type littermates (Pontoglio et 
al., 1998).  However, insulin secretion in response to arginine by Tcf1 -/- islets 
was about 13% of the insulin response found in Tcf1 +/+ islets; a similar 
decrease in insulin secretion by Tcf1 -/- was found with glucose stimulation 
(Pontoglio et al., 1998).  Thus, decreased insulin content cannot account for the 
decrease in insulin secretion by the Tcf1 -/- islet.  Other parts of the insulin 
secretion pathway need to be examined.   
 
1.5  Insulin secretion mechanisms 
 Insulin secretion by pancreatic beta-cells is a physiologic response to 
changes in their environment (for example, changes in the extracellular glucose 
concentration), that has been adapted to maintain fuel homeostasis in the entire 
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organism.  To stimulate insulin secretion, glucose is first taken up and 
metabolized by the pancreatic beta-cell.  Glycolysis leads to an increase in the 
ATP/ADP ratio that leads to closure of ATP-sensitive potassium channels.  The 
ATP-sensitive potassium channels are normally open for the positively charged 
potassium ions to leave the cell, following the electrochemical gradient.  Upon 
their closure, potassium is sequestered inside the cell, which leads to 
depolarization of the cell membrane.  Calcium is then released into the cytoplasm 
via voltage-dependent calcium channels, which in turn leads to extracellular 
release of insulin from the insulin-containing granules of the cell.   
In addition, the metabolism of glucose leads to an increase in cAMP, from 
the cyclization of the generated ATP by adenylate cyclases.  This increase in 
cAMP leads to activation of protein kinase A (PKA).  PKA inactivates ATP-
sensitive potassium channels, leading to increased membrane depolarization.  In 
addition, both PKA and cAMP-regulated guanine nucleotide exchange factor II 
(cAMP-GEFII) increase mobilization of calcium from intracellular stores, which 
further increases the release of insulin granules.   
The gastrointestinal tract also secretes hormones as a physiologic response 
to changes in food intake, which allow the body to adapt to maintain fuel 
homeostasis.  The glucose-dependent insulinotropic polypeptide (GIP) and the 
glucagon-like peptide 1 (GLP-1) have been the most studied of these gut-derived 
peptide hormones.  These peptide hormones which cause an augmentation of the 
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insulin secretion response after oral glucose intake compared with intravenous 
glucose intake are termed incretin hormones.   
GIP is a peptide secreted from K-cells that are found in the small intestinal 
mucosa, mostly in the duodenum (Mortensen et al., 2003).  GIP plasma 
concentration is increased 10- to 20-fold following meal ingestion, with secretion 
stimulated by carbohydrates and lipids.  Interaction between GIP and its receptor 
on islet cells, a type II G protein-coupled receptor, causes an increase in cAMP 
levels that lead to increased insulin secretion via the mechanisms described 
above.   
GLP-1 is secreted by L-cells of the intestinal mucosa.  Binding of GLP-1 to 
the GLP-1 receptor, a member of the same family as the GIP receptor, causes 
activation of adenylate cyclase resulting in an increase in cAMP formation, as 
with GIP (Mayo et al., 2003; Holz, 2004).  GLP-1 also stimulates gene 
transcription and biosynthesis of insulin (Fehmann and Habener, 1992), as well 
as transcription of other genes involved in insulin secretion, such as glucokinase 
and GLUT2 (Buteau et al., 1999).  In addition, GLP-1 has been shown to stimulate 
beta-cell proliferation and inhibit beta-cell apoptosis (Stoffers et al., 2000; Xu et 
al., 1999; Farilla et al., 2003; Li et al., 2003).  Studies with a GLP-1 receptor 
antagonist suggest that GLP-1 plays a significant role in controlling post-prandial 
glucose levels with oral glucose intake in rats (Kolligs et al., 1995; Wang et al., 
1995), as well as in humans (Edwards et al., 1999).   
10 
Amino acids also enhance insulin secretion from pancreatic beta-cells.  In 
particular, L-leucine, L-glutamine, L-alanine, and L-arginine have been studied 
for their insulinotropic effects.  Leucine is transaminated to alpha-
ketoisocaproate and enters the TCA cycle via acetyl-CoA, thus increasing ATP 
production (Panten et al., 1972).  In addition, leucine increases mitochondrial 
metabolism by allosterically activating glutamate dehydrogenase (GDH) in the 
islets (Sener and Malaisse, 1980; Gylfe, 1976).  In contrast, glutamine alone does 
not stimulate insulin secretion or potentiate insulin secretion induced by glucose 
(Sener et al., 1982); however, it enhances the insulin secretion induced by leucine 
(Sener and Malaisse, 1980).  It is believed that this is due to the allosteric 
activation of GDH by leucine, which increases entry of glutamine into the TCA 
cycle.  Alanine is also believed to stimulate insulin secretion through metabolism 
and entry into the TCA cycle (Brennan et al., 2002).  In addition, studies in 
insulin-secreting cell lines suggest that alanine can also stimulate insulin 
secretion electrogenically, due to co-transport with Na+ leading to membrane 
depolarization (Dunne et al., 1990; McClenaghan et al., 1998).   
Although arginine can be metabolized into components of the glycolytic 
pathway, the mechanism of arginine-induced insulin secretion does not rely on 
metabolism of arginine since non-metabolizable analogs of arginine can also 
stimulate insulin secretion (Smith et al., 1997).  Arginine-induced insulin 
secretion also is not related to the generation of nitric oxide, although arginine is 
also a substrate for nitric oxide synthase, as the nitric oxide synthase inhibitor, L-
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NMMA, does not inhibit insulin secretion (Smith et al., 1997; Henningsson and 
Lundquist, 1998).  Instead, it is believed that arginine stimulates insulin secretion 
by directly depolarizing the cell through its entry, since it is a basic amino acid 
carrying a positive charge (Figure 1).  In agreement with this theory, it has been 
shown that arginine cannot further stimulate insulin secretion in maximally 
depolarized islet cells.  Furthermore, arginine analogs that still carry a positive 
charge, such as the nitric oxide inhibitor L-NMMA, can also stimulate insulin 





1.6  Insulin secretion defects in the Tcf1 -/- pancreatic islets 
 As described before, Tcf1 -/- mice have a defect in glucose-induced 
insulin secretion.  Through whole-cell voltage clamp experiments, it was found 
that the ability of glucose to induce closure of ATP-dependent potassium 
channels is significantly reduced in Tcf1 -/- beta-cells compared to Tcf1 +/+ and 
+/- beta-cells (Dukes et al., 1998).  In contrast, the ability for membrane 
depolarization to trigger calcium influx is intact in the Tcf1 -/- islets (Pontoglio et 
al., 1998).  Thus, the defect in Tcf1 -/- insulin secretion pathway lies upstream of 
membrane depolarization.   
 Tcf1 -/- mice also have a defect in arginine-induced insulin secretion.  In 
contrast to glucose, which depolarizes the beta-cell via closure of ATP-dependent 
potassium channels, arginine is believed to depolarize the beta-cell itself upon 
entry.  Since the insulin secretion pathway downstream of membrane 
depolarization is intact in Tcf1 -/- beta-cells, the defect in arginine-induced 
insulin secretion may be due to a decrease in arginine uptake.  Thus, the study of 
arginine transporters and their regulation by Tcf1 may be the key to identifying 
the molecular players involved in arginine-induced insulin secretion and 
understanding the Tcf1 -/- beta-cell pathology.   
 
1.7  Arginine transporters 
 Arginine transport into cells can be mediated by four established classes 
of cationic amino acid transporters: system y+, system y+L, system b0+, and 
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system B0+ (Deves and Boyd, 1998).  These classes have been defined based on 
ion dependency, substrate specificity, and relative affinity.  In addition to these 
four systems, there is also a member of system N that has is reported to transport 
arginine; however, arginine transport by this transporter has not been well-
characterized.  The general characteristics of each family is outlined in Table 2.   
 
 System y+ is made up of four members: CAT1, CAT2, CAT3, and CAT4, 
which are encoded by Slc7a1, Slc7a2, Slc7a3, and Slc7a4, respectively.  In contrast 
to members of the other classes, these transporters are selective for cationic 
amino acids only (Verrey et al., 2004).  Each transporter has 14 putative 
transmembrane domains and is glycosylated.  Cationic amino acid transport 
mediated by these transporters is Na-independent.  Within this family, CAT1, 
CAT2, and CAT3 are more closely related to each other (~60% identity) than to 
14 
CAT4 (~40% identity) (Verrey et al., 2004).  The function of CAT4 has been under 
debate: while it was first characterized as being able to mediate cationic amino 
acid transport (Sperandeo et al., 1998), other groups have not been able to detect 
this activity (Wolf et al., 2002).   
 System y+L activity is mediated by heterodimeric transporters, comprised 
of a heavy chain subunit, 4F2hc, encoded by Slc3a2, linked via disulfide bonds to 
a light chain subunit, either y+LAT-2 or y+LAT-1, encoded by Slc7a6 and Slc7a7, 
respectively.  The light chain subunits contain 12 putative membrane-spanning 
domains and are not glycosylated. The heavy chain subunit, 4F2hc, is a single 
membrane-spanning glycoprotein, and is required for surface expression of the 
light chains (Wagner et al., 2001).  These transporters mediate Na-independent 
transport of cationic amino acids, as well as the Na-dependent uptake of neutral 
amino acids (Deves et al., 1992; Torrents et al., 1998).  While the physiological 
role of y+LAT-2 is not clear at present, mutations in y+LAT-1 have been found to 
be the underlying cause of the hereditary lysinuric protein intolerance disease 
(Shoji et al., 2002; Sperandeo et al., 2005).   
 System b0+ activity is mediated through a heterodimer of b0+AT 
(encoded by Slc7a9) and rBAT (encoded by Slc3a1).  It is characterized by Na-
independent transport of cationic and neutral amino acids.  The heterodimer is 
primarily expressed in the small intestine and the kidney, where it is localized to 
the basolateral membrane, as well as in the pancreas (Bertran et al., 1993).  Like 
y+LAT-1 and y+LAT-2, b0+AT has 12 putative transmembrane domains.  rBAT, 
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similar to 4F2hc, has only one transmembrane domain and is glycosylated.  
Mutations in rBAT have been linked to cystinuria, a hereditary disease that 
involves defective transepithelial transport of cystine and dibasic amino acids in 
the kidney and intestine (Calonge et al., 1994).   
 System B0+ activity is mediated by ATB0+ (encoded by Slc6a14), a 
member of the neurotransmitter transporter family, and is characterized by Na- 
and Cl-dependent cationic and neutral amino acid transport.  It has been shown 
that the SLC6A14 is associated with obesity through genetic screening of obese 
Finnish families (Suviolahti et al., 2003).  It was hypothesized that the transporter 
may be important for increasing the availability of tryptophan, which is used to 
synthesize serotonin, a neurotransmitter that increases satiety.  This would be 
due either to an increase of amino acid absorption from the intestinal tract, or to 
increased uptake by target cells.  In addition, ATB0+ is believed to play a key 
role in transepithelial transport of arginine in airway cells, which is important for 
providing a substrate for nitric oxide synthase to airway cells, as well as 
regulating the amino acid concentration in airway surface fluids (Galietta et al., 
1998; Rotoli et al., 2005).   
 mNAT3 (encoded by Slc38a4) was first characterized by Sugawara et al. as 
an amino acid transporter expressed mainly in the liver.  The transporter was 
named ATA3, since they had classified it originally as a system A amino acid 
transporter (2000).  The group further characterized the transporter as mediating 
both neutral and cationic amino acid transport, with a higher affinity for cationic 
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amino acids (Hatanaka et al., 2001).  However, uptake at different doses and 
kinetic studies of cationic amino acid transport was not performed in these 
studies.  Slc38a4 was later classified as a system N amino acid transporter, due to 
its inability to transport methylaminoisobutyric acid, which is a characteristic of 
the system A transporters.  In addition, in these later studies there was no 
detectable transport of cationic amino acids by mNAT3 (Gu et al., 2003).  Thus, 
the ability of mNAT3 to mediate cationic transport is unclear. 
 
1.8  Experimental study 
 We were interested in understanding the mechanism of arginine-induced 
insulin secretion and the molecules involved.  Tcf1 -/- mice provided us with a 
unique model to identify molecules that are involved in arginine uptake by 
pancreatic beta-cells.  Tcf1 -/- mice have a defect in arginine-induced insulin 
secretion and functional analysis of the Tcf1 -/- beta-cells have demonstrated 
that this defect is upstream of membrane depolarization.  Since arginine is 
believed to stimulate insulin secretion by direct depolarization of the beta-cell 
upon uptake, a defect in arginine-induced insulin secretion may be cause by 
decreased arginine uptake.   
We hypothesized that the defective arginine-induced insulin secretion in 
Tcf1 -/- mice is due to a defect in arginine uptake.  In this thesis, we sought to 
identify the transporters that may be involved in uptake of arginine by beta-cells.  
We characterized arginine uptake by insulin secreting cells, as well as arginine 
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transport by the Slc38a4 gene product, mNAT3, which had not been well-
characterized but was believed to mediate cationic amino acid transport.  In 
addition, we examined the expression and regulation by Tcf1 of arginine 
transporters in insulin-secreting cells through both gene expression arrays 
analysis and RT-PCR screening.  
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CHAPTER 2 -- RESULTS PART I 
 
2.1  Characterization of arginine uptake by MIN6 cells 
 We hypothesized that cellular entry of arginine into the pancreatic islet 
cell and the subsequent membrane depolarization were sufficient to stimulate 
insulin secretion.  Since arginine transport is the key step in arginine-induced 
insulin secretion, we first sought to characterize arginine uptake by insulin-
secreting cells.  Radioactive ligand uptake assays were performed on monolayers 
of mouse insulinoma cells (MIN6).   
 
2.1.1  Timecourse of arginine uptake by MIN6 cells 
We assayed the amount of arginine uptake by MIN6 cells over ten 
minutes using uptake buffer containing 10μM arginine.  Uptake of 3H-arginine in 
Tyrode’s solution was found to be linear over four minutes (Figure 2).  




2.1.2  Dose-dependence of arginine uptake by MIN6 cells 
 We assayed 3H-arginine uptake with arginine concentrations ranging 
from 10nM to 20mM in the uptake buffer.  Uptake was measured after two 
minutes.  We found that MIN6 cells take up arginine in a dose-dependent 
manner (Figure 3).   
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2.1.3  Kinetics of arginine uptake by MIN6 cells 
To determine the Michaelis-Menten constant, Km, and the maximum 
velocity, Vmax, of arginine uptake by MIN6 cells, we measured the uptake of 
arginine after two minutes with varying concentrations of arginine.  Inverse 
velocity was plotted against inverse arginine concentration to obtain a 
Lineweaver-Burk plot (Figure 4).  The inverse y-intercept, taken as Vmax, was 
0.154 pmoles/μg total protein per second.  By multiplying the Vmax to the slope 
of the line, we calculated the Km of MIN6 arginine uptake to be 102.6μM.   
21 
 
2.1.4  Effect of ion substitution on arginine uptake by MIN6 cells 
 In addition to determining the kinetics of arginine uptake by MIN6 cells, 
we wanted to further characterize uptake based on Na- and Cl-dependence.  To 
address this, we modified the uptake buffer to be either Na- or Cl-free and 
determined the effect on arginine uptake.  For the Na-free experimental buffer, 
we replaced NaCl with choline chloride and used KOH instead of NaOH to 
adjust the pH.  For the Cl-free experimental buffer, we replaced Cl with 
gluconate for NaCl, KCl, and CaCl2; MgCl2 was replaced with MgSO4.  We found 
a 37% decrease in arginine uptake with the Na-free buffer, while substitution of 
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Cl lead to no significant change in uptake (p>0.05 by student’s t-test).  Thus, 
arginine uptake by MIN6 cells is partly Na-dependent and is Cl-independent.   
 
2.2  Gene expression array analysis of Tcf1 +/+ and Tcf1 -/- pancreatic islets 
 Since arginine-induced insulin secretion depends on the depolarization 
upon cellular entry, we hypothesized that the arginine-induced insulin secretion 
defect in the Tcf1 -/- mice may be due to a defect in arginine uptake.  Thus, by 
studying the transport of arginine into insulin-secreting cells and the 
transporters that mediate it, we may better understand the molecular basis of this 
phenotype.  To identify any factors that may contribute to the defect in insulin 
secretion in the Tcf1 -/- mice, we analyzed gene expression in pancreatic islets 
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using Affymetrix oligonucleotide expression probe arrays, MG-U74A, MG-U74B, 
and MG-U74C.   
Two RNA samples were generated from pancreatic islets of either Tcf1 
+/+ or Tcf1 -/- mice.  The RNA from the islets of roughly fifty mice was pooled 
to generate each RNA sample.  Two probe sets were made from each RNA 
sample, and each probe was analyzed on separate chips.  Gene expression 
analysis values differed by less than 2% for the two probe sets generated from 
the Tcf1 +/+ RNA, and by less than 10% for the two probes generated from the 
Tcf1 -/- RNA, verifying consistency in probe generation and in gene chip 
hybridization.  Comparison of gene expression levels between Tcf +/+ and -/- 
samples were performed using Microarray Suite 4.0.   
Since Tcf1 is known to be a transcriptional activator, only genes that were 
expressed at higher levels in Tcf1 +/+ islets were considered as potential direct 
targets of Tcf1.  We identified the amino acid transporter gene, Slc38a4, which 
encodes mNAT3, as a potential target of Tcf1 through the gene chip screen with 
approximately 15.8-fold increased expression in the Tcf1 +/+ samples compared 
to Tcf1 -/- samples (Table 3).  Five other genes of arginine transporters were 
represented on the gene chips: Slc7a1, Slc7a2, Slc7a3, Slc7a7, and Slc7a9.  All of 
these other transporters represented on the microarray showed too low levels of 
expression to demonstrate a difference in expression levels between Tcf1 +/+ 
and Tcf1 -/- samples upon data analysis, except for Slc7a7, which had 
“decreased” levels in the Tcf1 +/+ samples. 
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2.3  Characterization of arginine transport by Slc38a4 
 The Slc38a4 gene product, mNAT3, was originally characterized by 
Hatanaka et al. as being able to mediate transport of cationic amino acids, 
including arginine (2001).  However, a rigorous demonstration of arginine 
uptake and a characterization of the transport kinetics were absent from this 
study.  Thus, we performed radioactive ligand uptake studies to investigate 
whether mNAT3 does indeed transport arginine and to define the kinetics of this 
transport.   
 
2.3.1  Timecourse of arginine transport by mNAT3 
 We studied the transport activity of mNAT3 by overexpressing it in COS-
7 cells.  COS-7 were transfected with either an mNAT3 expression vector or with 
an empty pcDNA3 vector.  Overexpression of mNAT3 protein was verified by 
Western blot (Figure 6A).  Radioactive ligand uptake assays were performed on 
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both mNAT3-transfected and pcDNA3-transfected COS-7 cells in parallel.  
mNAT3-mediated transport was calculated by subtracting the uptake by 
pcDNA3-transfected cells from that of the mNAT3-transfected cells.  We 
measured the uptake of 3H-arginine over 20 minutes with an uptake buffer 
containing 10μM arginine.  We determined that arginine uptake is linear over 
this time period.  Thereafter, arginine uptake was measured after two minutes.   
 
 
2.3.2  Dose-dependence of arginine transport by mNAT3 
 Arginine uptake by COS-7 cells overexpressing mNAT3 was assayed with 
buffers containing various amounts of arginine, ranging from 10nM to 20mM.  
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Uptake was assayed after two minutes, and the 3H-arginine uptake by pcDNA-
transfected COS-7 cells was subtracted from the uptake of mNAT3-transfected 
cells to obtain the arginine uptake due to mNAT3.  We determined that arginine 
uptake mediated by mNAT3 is dose-dependent (Figure 7). 
 
 
2.3.3  Kinetics of arginine transport by mNAT3 
We measured the mNAT3-mediated uptake of arginine with varying 
concentrations of arginine and plotted the inverse velocity against inverse 
arginine concentration to obtain a Lineweaver-Burk plot (Figure 8).  From this 
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plot, we determined the Vmax of mNAT3-mediated arginine uptake to be 0.039 
pmoles/s per μg total protein.  The Km was calculated to be 53μM.   
 
 
2.3.4  Effect of ion substitution on arginine transport by mNAT3 
 We also measured mNAT3-mediated arginine uptake in COS-7 cells using 
Na- and Cl-free buffers to determine whether this transport is Na- or Cl-
dependent.  In the absence of sodium, we found that arginine uptake by mNAT3 
was decreased by 55%.  In the absence of chloride, arginine uptake was 





2.4  Tissue expression of arginine transporters 
 We established that mNAT3 is a transporter of arginine.  To better 
understand its role in arginine uptake in insulin-secreting cells, we wanted to see 
which, if any, other arginine transporters were expressed in insulin-secreting 
cells.  We generated a cDNA tissue panel, to be able to look at relative RNA 
expression levels of the various amino acid transporters in different tissues.  
Using gene-specific primers, we performed RT-PCR with the tissue panel for 
each arginine transporter.  We found that of the eleven known arginine 
transporters, eight were expressed in islets and MIN6 cells (Figure 10).  In 
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addition to Slc38a4, insulin-secreting cells were determined to also express the 




2.5  Arginine transporter expression in Tcf1 +/+ and -/- pancreatic islets 
 Since we were interested in determining whether the arginine-induced 
insulin secretion defect in Tcf1 -/- mice could be due to a defect in arginine 
uptake by the insulin-secreting cells, we sought to determine which of these eight 
arginine transporters were regulated by Tcf1.  Using semi-quantitative RT-PCR, 
we examined the expression levels of each arginine transporter in a pancreatic 
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islet cDNA panel from Tcf1 +/+ and Tcf1 -/- mice.  Of the eight arginine 
transporters expressed in the islets, we found only Slc7a3, Slc7a7, and Slc38a4 to 
be expressed at significantly different levels in Tcf1 +/+ and Tcf1 -/- islets 
(Figure 11).  In good correlation to the results of the gene expression array 
results, Slc38a4 was found to be downregulated in the Tcf1 -/- islets compared to 
Tcf1 +/+.  In similar agreement to the gene expression array results, we found 
Slc7a7 to be upregulated in the Tcf1 -/- islets.  While the expression levels of 
Slc7a3 were too low to be able to yield a comparison between Tcf1 +/+ and -/- 
expression levels in the gene chip study, we found through RT-PCR that Slc7a3, 
like Slc38a4, is downregulated in the Tcf1 -/- islets.   
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2.6  Arginine uptake and insulin secretion with Slc38a4 (mNAT3) and Slc7a3 (CAT3) 
knockdown 
 We were interested to know whether a defect in arginine uptake by 
insulin-secreting cells was the cause of the defect in arginine-induced insulin 
secretion in Tcf1 -/- mice.  Since mNAT3 and CAT3 were the only arginine 
transporters whose gene expression was downregulated in Tcf1 -/- islets, we 
decided to knockdown expression of these two transporters in MIN6 cells to see 
if we could affect arginine uptake and insulin secretion.   
 
2.6.1  Knockdown of Slc38a4 (mNAT3) in MIN6 cells 
 We electroporated two siRNAs designed to target Slc38a4 into MIN6 cells 
to test the effect of Slc38a4 knockdown.  We confirmed knockdown of mNAT3 by 
Western blot (Figure 12).   
 
Radioactive ligand uptake assays with 3H-arginine were performed on 
MIN6 cells to compare arginine transport in cells electroporated with Slc38a4 
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siRNA with cells electroporated with a control siRNA.  We found a small but 
significant decrease in arginine uptake by MIN6 cells with Slc38a4 siRNA (Figure 
13).  Insulin secretion in response to arginine and leucine were also measured 






2.6.2  Knockdown of Slc7a3 (CAT3) in MIN6 cells 
 Two siRNAs designed to target Slc7a3 were electroporated into MIN6 
cells.  Knockdown of Slc7a3 in electroporated cells was confirmed by semi-
quantitative RT-PCR (Figure 15A).  We found that Slc7a3 knockdown led no 
significant change in arginine uptake (Figure 15B).  There was also no change in 
insulin secretion in response to arginine and leucine with Slc7a3 knockdown 




2.6.3  Knockdown of both Slc38a4 (mNAT3) and Slc7a3 (CAT3) 
 We also electroporated MIN6 cells with both Slc38a4 and Slc7a3 siRNA 
and examined arginine uptake and insulin secretion.  Using the maximal amount 
of siRNA for electroporation, we were unable to detect a change arginine uptake 
by cells with both Slc38a4 and Slc7a3 siRNA compared with cells with control 
siRNA.  When we performed insulin secretion assays on these cells, we found no 
change in glucose or leucine-induced insulin secretion, and a small increase in 
arginine-induced insulin secretion in the cells electroporated with Slc38a4 and 




CHAPTER 3 – DISCUSSION PART I 
 
3.1  Characterization of arginine uptake by insulin-secreting cells   
In this study, we identified eight arginine transporters to be expressed in 
pancreatic islet tissue.  All of these transporters, with the exception of y+LAT-1 
encoded by the Slc7a7 gene, are also expressed in MIN6 cells, a mouse 
insulinoma cells that constitute a more beta-cell-specific test sample.  Thus, we 
believe that y+LAT-1 may be exclusively expressed in the non-beta-cells of the 
pancreatic islets, such as the glucagon- or somatostatin-producing cells of the 
islet.   
The expression of seven different arginine transporters in MIN6 cells 
suggests that arginine uptake may be a highly redundant function in insulin-
secreting cells.  We also characterized the uptake of arginine by insulin-secreting 
cells using radioactive ligand uptake studies with MIN6 cells.  We determined 
the Km for arginine uptake by MIN6 cells to be 102.6μM.  This value for uptake 
kinetics is consistent with the notion that all seven arginine transporters 
expressed may be active in arginine uptake by insulin-secreting cells.  The 
reported Km values for the seven arginine transporters we have identified to be 
expressed in MIN6 cells range from 43μM to 120μM, with the exception of the 
CAT2A transporter encoded by Slc7a2 (Kim et al., 1991; Habermeier et al., 2003; 
Hosokawa et al., 1997; Pfeiffer et al. 1999; Wells et al., 1992).  The CAT2A 
transporter has a Km of 3mM, over ten-fold higher than the Km values of 
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arginine uptake by the other expressed transporters and of arginine uptake by 
MIN6 cells (Habermeier et al., 2003).  This significantly lower substrate affinity 
suggests that CAT2A may not have a large role in arginine uptake by insulin-
secreting cells.   
 We also determined that arginine uptake by MIN6 cells is partly Na-
dependent.  This finding is particularly striking because of the seven transporters 
expressed in MIN6 cells, all have been reported to be Na-independent for 
arginine transport except for mNAT3 encoded by the Slc38a4 gene, which we 
had characterized in this study as having partial Na-dependence.  This suggests 
that mNAT3 normally has a significant role in arginine uptake by MIN6 cells.  
However, our experiments with siRNA-mediated knockdown of mNAT3 
expression in MIN6 cells have demonstrated that mNAT3 activity is not crucial 
for proper arginine uptake and arginine-induced insulin secretion.  This further 
demonstrates the redundancy of arginine transport activity and the ability for the 
other arginine transporters to compensate for the loss of activity of one.   
 The redundancy of arginine transport function, which is directly linked to 
arginine-induced insulin secretion activity, is particularly interesting considering 
the clinical use of the arginine bolus test, in which a bolus of arginine is delivered 
to patients intravenously and resultant plasma insulin levels are determined.  
This test was commonly used in the clinic to diagnose insulin secretion defects, 
before the oral glucose tolerance test was developed.  Not much was then 
understood about the mechanism of arginine-induced insulin secretion and what 
38 
the test was measuring exactly.  Recent studies that have shown that arginine-
induced insulin secretion is due to electrogenic uptake of arginine into the cells 
have allowed the possibility that arginine-induced insulin secretion defects may 
result from defects in arginine uptake.  Our study, which shows seven arginine 
transporters that are expressed in insulin secreting cells and that are able to 
maintain normal levels of arginine uptake and arginine-induced insulin secretion 
with knockdown of two arginine transporters, suggests that arginine uptake in 
insulin-secreting cells is highly robust.  Thus, it is highly unlikely that any defect 
in insulin production from the arginine bolus test would be due to a defect in 
arginine uptake.  Instead, a defect would most likely be due to a decrease in 
insulin content, which is closely linked to islet mass within the pancreas.   
 
3.2  Implications for arginine-induced insulin secretion in Tcf1 -/- mice 
 Of the eight arginine transporter genes found to be expressed in islets, 
only Slc38a4 and Slc7a3 were found to be regulated by Tcf1, using semi-
quantitative RT-PCR analysis of pancreatic islet tissue.  Using siRNAs to knock 
down expression of these two transporter genes in MIN6 cells, we found that 
decreased expression of these genes had no effect on either arginine uptake or 
insulin secretion.  Thus, we were unable to mimic the insulin secretion defects 
found with Tcf1 deficiency with knockdown of these two transporters.  These 
results suggest that mNAT3 and CAT3 activity is not crucial to maintain normal 
arginine uptake and arginine-induced insulin secretion in insulin-secreting cells.   
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 We cannot exclude the possibility that the level of siRNA-mediated 
knockdown in our study was insufficient to see the effects of total loss of activity 
by these transporters.  It may be possible that the loss of transport activity by 
mNAT3 and CAT3 causes the defect in arginine-induced insulin secretion in the 
Tcf1 -/- mice, but that this cannot be modeled using siRNAs in MIN6 cells due to 
insufficient transporter knockdown in the MIN6 cells.  It is important to note, 
however, that even in the Tcf1 -/- islets, there is not complete knockdown of 
either transporter.   
 If loss of mNAT3 and CAT3 activity is not the cause of the arginine-
induced insulin secretion defect in the Tcf1 -/- mice, it is possible that there are 
other yet unidentified arginine transporters that are expressed in insulin-
secreting cells and are regulated by Tcf1, which we have not studied.  It is also 
possible that there is post-transcriptional regulation of arginine transporter 
expression and/or function that is affected in the Tcf1 -/- islets of the other 
arginine transporters.  mNAT3 and CAT3 were identified as the only arginine 
transporters downregulated in Tcf1 -/- pancreatic islets through RT-PCR of a 
cDNA panel from islets of Tcf1 +/+ and Tcf1 -/- mice.  Since Tcf1 is well-
characterized as a transcriptional activator, we sought to identify genes regulated 
by Tcf1 at the transcriptional level.  However it is possible that Tcf1 may either 
directly or indirectly affect the protein expression or activity of arginine 
transporters by a mechanism as yet unidentified.  Thus, impaired activity of 
another arginine transporter, which has no decrease in cDNA expression levels 
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in the Tcf1 -/- islets, may be the cause of defective arginine-induced insulin 
secretion in the Tcf1 -/- mice.   
To begin examining this possibility, it would be useful to systematically 
design siRNAs targeting the other arginine transporters expressed in MIN6 cells, 
and assay changes in arginine uptake and insulin secretion.  While this would 
not identify what causes the arginine-induced insulin secretion defect in Tcf1 -/- 
mice, it would identify any transporters with activity that is important for uptake 
and insulin-secretion function.   
 
3.3  Tcf1 as a master regulator of transporters 
 We have demonstrated that Tcf1 regulates the expression of amino acid 
transporters, encoded by the genes Slc7a3, Slc7a7, and Slc38a4.  As we were 
unable to mimic the arginine-induced insulin secretion defect with knockdown 
of Slc7a3 and Slc38a4, it is possible that Tcf1 regulates arginine uptake through 
regulation of additional transporters.  In addition to the defect in arginine-
induced insulin secretion, other characteristics of the Tcf1 -/- mouse suggest an 
important role for Tcf1 in regulating transmembrane transport of various 
compounds.   
Tcf1 -/- mice also have elevated plasma bile acid levels (Shih et al., 2001).  
This was found to be due to decreased expression of bile acid transporters on the 
basolateral membrane of hepatocytes, leading to decreased uptake of bile acids 
from the blood into the liver.  Bile acid transporter genes that have been shown 
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to be regulated by Tcf1 include Slc10a1, Slc21a3, Slc21a5, and Slc21a6 (Shih et al., 
2001; Jung et al., 2001).  In addition, Tcf1 -/- mice also have increased urinary 
and fecal bile acid excretion, which is believed to be secondary to decreased bile 
acid uptake in the ileum as well as in the kidneys from decreased expression of 
the bile acid transporter Slc10a2 expressed in these tissues (Shih et al., 2001).   
Tcf1 -/- mice also exhibit a renal Fanconi-like syndrome (Pontoglio et al., 1996).  
This is characterized by a defect in reabsorption of glucose, phosphate, and 
amino acids in the renal tubules, leading to glucosuria, phosphaturia, and 
aminoaciduria.  Tcf1 has been shown to regulate expression of the glucose 
transporter Slgt2, as well as sodium/phosphate cotransporters Npt1 and Npt4 
(Pontoglio et al., 2000; Cheret et al., 2002).  In addition to the Tcf1 -/- mouse 
model, MODY3 patients are also characterized by severe glucosuria, due to 
reduced glucose reabsorption in the renal proximal tubule.  Thus, the relevance 
of Tcf1 in regulating transmembrane transport exists not only in the mouse 
model, but also in actual MODY3 patients.    
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CHAPTER 4 
INTRODUCTION TO LIVER STUDIES 
 
4.1  Overview of insulin action 
 As discussed in Chapter 1, insulin is a polypeptide hormone that is 
secreted in response to increases in blood glucose, amino acids, and fatty acids 
levels.  Once secreted into the bloodstream, it is able to signal to different organs 
to adjust their fuel metabolism to maintain homeostasis in the organism.  Thus, 
in large part due to the action of insulin, plasma glucose remains in a range 
between 4mM and 7mM in normal individuals, despite periods of fasting and 
feeding (Saltiel and Kahn, 2001).  The metabolic effects of insulin are generally 
anabolic: as it signals a “fed” state in the organism, it promotes the synthesis of 
glycogen from glucose, triacylglycerols from fatty acids, and protein from amino 
acids.  Insulin also stimulates the insertion of glucose transporters into the cell 
membrane in tissues, such as muscle, to allow for glucose uptake by these 
tissues.  Since glucose is available from external sources, the organism does not 
need to generate glucose; thus, gluconeogenesis and glycogenolysis are shut off 
by insulin.  In the absence of insulin when nutrient intake is low, the body acts to 
maintain glucose levels through both glycogen breakdown and de novo 
synthesis of glucose.  In addition, the body generates ketone bodies through 




 A major target for insulin action is the liver.  When insulin levels are low, 
the liver becomes a site of hepatic glycogen breakdown, gluconeogenesis, β-
oxidation, and ketogenesis (Nordlie et al., 1999; Pilkis et al., 1992; Laffel, 1999).  
While gluconeogenesis also occurs in the kidneys, the liver is the site of 90% of 
gluconeogenesis in the body.  Hepatic glucose production is a key mechanism for 
providing the organism with glucose during periods of fasting, and is affected by 
the levels of available glucogenic substrates and the activity of regulatory 
enzymes.  Insulin is known to inhibit gluconeogenesis predominantly by 
decreasing the expression of genes or by changing the activity (by changing 
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phosphorylation states) for key enzymes in the gluconeogenesis pathway 
(Barthel and Schmoll, 2003).  Insulin also inhibits β-oxidation of fatty acids and 
promotes lipogenesis, mainly through regulating the transcription of genes for 
enzymes involved in those pathways.  We will discuss the molecular 
mechanisms of these insulin-regulated effects.   
 
4.2  Insulin receptor and insulin receptor substrates 
Insulin mediates its actions by binding to its receptor on target tissues.  
The insulin receptor is a member of a subfamily of receptor tyrosine kinases that 
includes the insulin-like growth factor-I receptor (IGFIR) and the insulin 
receptor-related receptor (IRR) (Patti and Kahn, 1998).  Two alpha-subunits and 
two beta-subunits make up the insulin receptor (reviewed by De Meyts and 
Whittaker, 2002). The alpha-subunits are entirely extracellular and contain the 
hormone-binding domains.  The alpha-subunits are each linked to a beta-subunit 
and to each other by disulfide bonds (White and Kahn, 1994).  The beta-subunits, 
which contain the ATP-binding and tyrosine kinase domains, pass through the 
cellular membrane.  In the absence of ligand, the alpha-subunit inhibits the 
tyrosine kinase activity of the beta-subunit.  Upon insulin binding to the alpha-
subunit, this repression of the beta-subunit kinase activity is released.  The two 
beta-subunits of the insulin receptor then transphosphorylate each other, leading 
to a conformational change that further increases kinase activity (Patti and Kahn, 
1998).  
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There are at least 11 intracellular substrates of the insulin receptor and the 
IGF1R kinases.  Of these, six belong to the family of insulin-receptor substrate 
(IRS) proteins.  Other substrates include Grb2-associated binder-1 (Gab1), Cas-
Br-M ecotropic retroviral transforming sequence homologue (Cbl), adaptor 
protein with a pleckstrin homology (PH) and Src homology 2 (SH2) domain 
(APS), and the SH2-containing protein (Shc) isoforms (Pessin and Saltiel, 2000). 
The IRS proteins have both PH domains and phosphotyrosine-binding 
(PTB) domains.  The PTB domains allow the IRS proteins to have high binding 
affinities for the activated insulin receptors.  The PH domains allow for binding 
to membrane phospholipids, and have also been found to be important for 
activation of downstream signaling molecules (Vainshtein et al., 2000).  In 
addition, the IRS proteins contain up to 20 potential tyrosine-phosphorylation 
sites, allowing for interactions with other molecules containing SH2 domains 
once they are phosphorylated by the insulin receptor tyrosine kinase.  IRS-1 and 
IRS-2 are widely expressed and implicated in regulation of metabolism.  IRS-3 is 
mainly expressed in the adipocytes and brain; IRS-4 is expressed primarily in 
embryonic tissues; IRS5/DOK4 is ubiquitously expressed, but most highly in the 
liver and kidney; and IRS6/DOK5 is most highly expressed in skeletal muscle 
(Taniguchi et al., 2006; Cai et al., 2003).   
While the IRS proteins are highly homologous to each other, knockout 
and knockdown studies have shown that they do not perform redundant roles.  
Biochemical studies have shown that IRS proteins have different binding 
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affinities for various SH2 proteins (Sun et al., 1997), providing at least one 
explanation for their differential functions.  In a study using adenovirus-
mediated RNA interference to knockdown IRS-1 and IRS-2 expression 
specifically in the livers of wild-type mice, it was found that knockdown of IRS-1 
was associated with a increase in gene expression of gluconeogenic enzymes 
glucose-6 phosphatase (G-6-P) and phosphoenolpyruvate carboxykinase 
(PEPCK), and a trend toward increased blood glucose levels (Taniguchi et al., 
2005).  In contrast, knockdown of IRS-2 in the liver resulted in increased hepatic 
lipid accumulation.  While IRS-1 and IRS-2 are implicated in different insulin 
signaling effects, they also play complementary roles and are able to compensate 
for the loss of the other to some extent.  For example, the upregulation of 
gluconeogenic enzymes observed with knockdown of IRS-1 was less than that 
observed with concommitant knockdown of IRS-2.  The hepatic knockdown of 
both IRS-1 and IRS-2 resulted in systemic insulin resistance, glucose intolerance, 
and hepatic steatosis (Taniguchi et al., 2005).    
 
4.3  Insulin-regulated signaling pathways 
Insulin binding to the insulin receptor leads to activation of two separate 
signal transduction cascades: 1. the mitogen-activated protein kinase (MAPK) 





The adaptor molecule growth-factor-receptor-bound protein 2 (Grb2) 
binds to phophorylated IRS proteins.  Grb2 constitutively associates with son-of-
sevenless (Sos), the guanine nucleotide exchange factor for Ras, which is located 
on the plasma membrane.  Binding of Grb2 to phosphorylated IRS proteins 
brings Sos to the plasma membrane to Ras, activating its GTPase, which then 
stimulates Raf-1.  Raf-1 is a serine/threonine kinase that activates mitogenic 
effector kinase (MEK), which in turn activates MAPK (Myers et al., 1994).  
Activation of this pathway by phorbol myristate acetate (PMA) was found to 
suppress the transcription of the PEPCK and G-6-P genes (Schmoll et al., 2001; 
Gabbay et al., 1996).  However, neither pharmacological inhibitors of MAPK (PD-
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98059, PD-184352, and U-0126) nor overexpression of dominant negative mutants 
of Ras affects the regulation by insulin of PEPCK and G-6-P gene expression 
(Agati et al., 1998; Schmoll et al., 2001, Gabbay et al., 1996; Sutherland et al., 
1998).  Thus, the physiological importance of the MAPK pathway in insulin-
regulated hepatic metabolism is unclear.   
PI3K is comprised of a regulatory subunit and a catalytic subunit.  Kinase 
activity of the enzyme requires interaction of the SH2 domains in the regulatory 
subunit with phosphotyrosines in the IRS proteins.  PI3K catalyzes the formation 
of phospholipid PIP3 via phosphorylation of PI(4,5)P2.  Proteins with PH 
domains that bind PIP3 are then recruited to the cell membrane, where they are 
activated.  Among those proteins activated via the PI3K pathway are members of 
the AGC superfamily of serine/threonine protein kinases, such as 3-
phophoinositide-dependent protein kinase 1 (PDK1), which phosphorylates and 
activates the serine/theonine kinase Akt/PKB, glycogen synthase kinase-3 (GSK-
3), as well as atypical forms of protein kinase C, aPKCs, such as PKCλ and PKBξ.  
Many transcription factors are regulated via the PI3K signaling pathway.  
Pharmacological inhibitors of PI3K (wortmannin and LY-294002) can abolish the 
insulin-induced suppression of PEPCK and G-6-P gene expression (Agati et al., 
1998; Dickens et al., 1998).  Adenovirus-mediated overexpression of a dominant 
negative mutant of the PI3K regulatory subunit, which cannot bind to the 
catalytic subunit, increases PEPCK and G-6-P gene expression and hepatic 
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glucose production (Miyake et al., 2002).  Thus, the PI3K pathway is a key 
mediator of hepatic insulin effects.   
 
4.4  Transcription factors involved in insulin-regulated hepatic metabolism 
 Many of insulin’s effects in the liver are mediated through transcriptional 
regulation of genes involved in metabolic processes.  A number of transcription 
factors and coactivator proteins have been identified as being involved in the 
insulin signaling process.  In this section, we will describe the sterol response 
element-binding protein (SREBP)-1c, the liver X-activated receptor (LXR)α and 
LXRβ, and peroxisome proliferator-activated receptor-γ coactivator-1 (PGC-1).  
The forkhead members of transcription factors, which may be regulated by 
insulin via the PI3K pathway, will be discussed in the next section.   
 Through activation of PI3K, insulin stimulates transcription of the SREBP-
1c gene in hepatocytes, as well as in adipose and muscle cells (Foufelle and Ferre, 
2002).  In addition, activation of Akt/PKB in vitro was found to be sufficient for 
upregulation of SREBP-1c gene expression (Fleischmann and Iynedjian, 2000).  
Adenovirus-mediated overexpression of SREBP-1c has been found to decrease 
gene expression of PEPCK in vitro and in vivo (Chakravarty et al., 2001; Becard 
et al., 2001).  SREBP-1c overexpression also decreases hyperglycemia in diabetic 
mice (Becard et al., 2001).  SREBP-1c can also increase transcription of lipogenic 
genes, such as acetyl-CoA synthetase, fatty acid synthase, acetyl-CoA 
carboxylase (Edwards et al., 2000; Osborne, 2000).  Thus, by increasing 
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expression of SREBP-1c, insulin can decrease gluconeogenesis and increase 
lipogenesis.   
 Insulin signaling also induces expression of LXRs.  LXRα, which is 
expressed mainly in liver, kidney, and intestines, and LXRβ, which is expressed 
ubiquitously, belong to the nuclear receptor superfamily (Edwards et al., 2002).  
The endogenous activating ligands of the LXRs are oxysterols, allowing the 
factors to sense changes in cholesterol levels.  In fact, LXRα has been found to be 
important for the response to administration of cholesterol-enriched diets in mice 
(Peet et al., 1998).  LXRs form heterodimers with the retinoic acid receptor-α 
(RXR) to bind to response elements in their target genes, activating expression of 
genes involved in lipogenesis, bile acid formation, and cholesterol transport, 
such as fatty acid synthase, cholesterol 7α-hydroxylase, and ABCA1.  In addition, 
LXR has been shown to also increase expression of SREBP-1c.  LXR agonists can 
decrease blood glucose in rodent models, at least in part through suppression of 
gluconeogenic enzyme expression (Cao, et al., 2003; Stulnig et al., 2002).  This 
may be through direct interaction of LXR with these target genes, or through an 
indirect mechanism, such as through regulation of SREBP-1c.   
 PGC-1 is a coactivator protein that is positively regulated by glucagon via 
cAMP.  In vitro studies using PGC-1 promoter-reporter gene plasmids 
transfected into HepG2 cells show that insulin suppresses PGC-1 promoter 
activity and that this suppression can be mimicked with coexpression with 
Akt/PKB (Daitoku et al., 2003).  In addition, these in vitro studies suggest that 
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PGC-1 is a direct target of Foxo1, a forkhead transcription factor that is 
inactivated by Akt/PKB.  PGC-1 acts to increase gluconeogenesis, by increasing 
transcription of gluconeogenic enzymes.   
 
4.5  Forkhead family of transcription factors 
 Foxo1 and Foxa2 are two other transcription factors that are regulated by 
insulin.  Foxo1 and Foxa2 are both members of the forkhead family of 
transcription factors.  Forkhead proteins are a large family of functionally diverse 
transcription factors, which are involved in a variety of cellular processes, such 
as cranial and neural development, immune regulation, pancreatic and liver 
development, as well as liver metabolism (Lehmann et al., 2003; Coffer and 
Burgering, 2004; Lee, et al., 2004; Lee et al., 2005; Nakae et al., 2002; Wolfrum et 
al., 2004).   
 The original fork head (fkh) gene was identified in Drosophila melanogaster, 
through a screen of embryonic lethal mutants.  It was found to be required for 
terminal pattern formation in the embryo (Weigel et al., 1989).  The year 
following the identification of fork head, a novel group of liver-specific 
transcription factors was identified whose members have DNA-binding domains 
with a high degree of homology to that of the fkh gene product (Lai et al., 1990).  
This family was called the hepatic nuclear factor 3 (HNF3) family.  Since then, 
many transcription factors with this forkhead motif have been identified in a 
whole range of organisms, from yeast to humans.   
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 More than a hundred members of the forkhead transcription factor family 
have been identified to date, leading to a change in the nomenclature (Kaestner 
et al., 2000).  Fox (for “forkhead box”) is now used to name all chordate forkhead 
transcription factors, followed by a letter denoting its subfamily based on 
phlyogenetic analysis (not based on function).  Each gene from a subfamily of 
Fox proteins is then identified by a number.  Fox proteins all share a highly 
conserved DNA-binding domain, which forms a butterfly-like structure when 
bound to DNA, giving it the description “winged helix” (Clark et al., 1993).  
Since most of the amino acids within this DNA-binding domain are conserved, it 
is not understood how Fox transcription factors have different DNA sequence 
specificity.  In contrast to the highly conserved DNA-binding domain, the 
transactivation or transrepression domains of the Fox family have little 
homology.   
 Foxo1 and Foxa2 are forkhead family transcription factors that are 
regulated by insulin.  Foxo1 promotes gluconeogenesis (Nakae et al., 2001; Nakae 
et al., 2002), while Foxa2 regulates fatty acid metabolism (Wolfrum et al., 2004).  
Insulin signaling results in activation of Akt/PKB, which then phosphorylates 
Foxo1 and Foxa2 (Brunet et al., 1999; Biggs et al., 1999; Wolfrum et al., 2003).  
Phosphorylation leads to nuclear exclusion of these transcription factors, thus 





 A mutant form of Foxa2 was generated, changing the phosphorylated 
threonine at position 156 to alanine.  This resulted in a constitutively active form 
of Foxa2, which could remain localized in the nucleus even with insulin present 
(Wolfrum et al., 2004).  When adenovirus expressing this constitutively active 
form of Foxa2, called Foxa2 (T156A), was injected into hyperinsulinemic mice, 
where endogenous Foxa2 is permanently inactive due to the high amounts of 
insulin present, decreases in hepatic triglyceride content, increases in plasma 
triglyceride levels, and increases in ketone bodies in the plasma were noted.  On 
the other hand, haploinsufficient Foxa2 +/- mice have decreased levels of 
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ketogenesis and β-oxidation (Wolfrum et al., 2004).  The data suggest that Foxa2 
is an important insulin-regulated mediator of lipid metabolism, actively 
promoting ketogenesis and β-oxidation during fasting when insulin levels are 
low.   
 
4.6  Insulin signaling and amino acid uptake 
 Insulin promotes an anabolic state in the organism, leading to increased 
amino acid uptake by muscle cells for protein synthesis (Biolo et al., 1995).  In the 
absence of insulin, or in insulin-resistant states, muscle breakdown increases 
without this anabolic stimulus.  In fact, age-related insulin resistance has recently 
been proposed to be a cause of the loss of muscle mass and strength (sarcopenia) 
observed in elderly individuals (Rasmussen et al., 2006).  Because of this 
regulation, during times of fasting, when insulin in not present, protein synthesis 
is decreased and less amino acids are taken up by skeletal muscle.   
 In contrast, studies have shown that hepatic amino acid uptake and 
metabolism increases in the liver during periods of fasting (Low et al., 1992; 
Grofte et al., 1999; Gu et al., 2005).  This effect helps to provide more amino acids 
to the liver cells, which need to increase gluconeogenesis during fasting.  It was 
found that hepatic nitrogen clearance, a measure of hepatic amino acid 
metabolism, decreases with a hyperinsulinemic and euglycemic clamp in normal 
and healthy individuals, suggesting that insulin plays a direct role in regulation 
(Grofte et al., 1999).  However, with a hyperinsulinemic and hypoglycemic 
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clamp, hepatic nitrogen clearance increases despite the high insulin levels, 
suggesting that there is another level of regulation that hypoglycemia may 
trigger, to counteract the effect of insulin.   
 While these effects of fasting and feeding on hepatic amino acid uptake 
and metabolism have been long known, the molecular mechanisms governing 
these processes had not been studied until recently with a study on a system N 
amino acid transporter, SNAT3, encoded by Slc38a3 (Gu et al., 2005).  In this 
study, it was found that SNAT3 expression is downregulated by insulin.  This 
downregulation could be blocked by the PI3K inhibitor, LY294002, but not by the 
MAPK inhibitor, PD98059.  This data not only demonstrate that insulin that 
regulate expression of an amino acid transporter, but that it is through the PI3K 
signaling pathway that insulin induces this effect.   
 
4.7  Experimental study 
 We had identified the Slc38a4 gene, encoding the amino acid transporter 
mNAT3, as being expressed in pancreatic islet cells and regulated by the 
transcription factor Tcf1.  We had also shown that Slc38a4 is highly expressed in 
the liver as well.  In this study, we analyzed the regulation of Slc38a4 by Tcf1 in 
the liver as well as the pancreatic islets.  We also hypothesized that Slc38a4 may 
be regulated by metabolic states and endeavored to identify the molecular basis 
for this regulation. 
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CHAPTER 5 -- RESULTS PART II 
 
5.1  Tcf1 regulation of Slc38a4 in the pancreatic islets and the liver 
 We examined the expression and regulation of Slc38a4 in the liver, where 
it was strongly expressed in addition to in the pancreatic islets (Figure 10).  By 
semi-quantitative RT-PCR using liver tissue from Tcf1 +/+ and -/- mice, we 
found that Slc38a4 is also regulated in the liver, but not as strongly as in the 
pancreatic islets (Figure 21).  We were interested in this difference in Tcf1 
regulation, and wanted to discover the basis for this. 
 
5.2  Alternative transcriptional start sites for Slc38a4 
 One possibility we examined for the difference in Tcf1 regulation of 
Slc38a4 was differential transcriptional start sites.  We performed 5’ RACE on 
RNA from pancreatic islets.  Sequencing of the 5’ end of the islet Slc38a4 
transcript revealed an alternative first and second exon of Slc38a4, compared 
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with the Slc38a4 mRNA sequence from liver cDNA libraries (Genbank accession 
no. BC024123).  These two transcript isoforms differ only in their 5’ untranslated 
region; the open reading frames are identical, and hence, they encode identical 
proteins (Figure 22A).  RT-PCR using isoform-specific primers showed that while 
the liver contains both transcript isoforms of Slc38a4, the islet contains only one 
isoform, which we termed the “islet” isoform (Genbank accession no. AY027919) 
(Figure 22B).  We termed the originally identified Slc38a4 transcriptional isoform 
the “liver” isoform.   
 
5.3  Tcf1 regulation of both transcriptional isoforms of Slc38a4 
We investigated if both transcriptional isoforms of Slc38a4 were regulated 
by Tcf1.  To address this question, we performed RT-PCR of the two isoforms in 
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a panel of liver Tcf1+/+ and Tcf1-/- mice.  We found that the “islet” isoform of 
Slc38a4 (which is present in both liver and islet) is strongly regulated by Tcf1, 
while the “liver” isoform is regulated as well, but to a lesser degree (Figure 23).   
 
5.4  Regulation of Slc38a4 in the liver by metabolic states and insulin 
 The liver responds to fasting by increasing the uptake of amino acids, 
which are then used as carbon skeletons for the generation of glucose.  Since we 
had shown that Slc38a4 mediated the uptake of arginine into cells, as well as 
neutral amino acids (shown by other groups), we questioned whether it could 
have a role in the hepatic response to fasting.  We generated a panel of liver 
cDNA from mice that had been fasted overnight, fed control mice, and 
overnight-fasted mice that had been injected with 10ng insulin by portal vein 
injection.   
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We found that Slc38a4 expression is upregulated during fasting.  In 
addition, using isoform-specific primers, we found that both Slc38a4 transcript 
isoforms were upregulated by fasting (Figure 24A).  Furthermore, this 
upregulation of Slc38a4 was dependent on the absence of insulin, since it is 
abolished with the injection of insulin into the overnight-fasted mice.  
Interestingly, this upregulation of Slc38a4 by fasting was not observed in the 





5.5  Slc38a4 is regulated by Foxa2 
 We then examined Foxa2 as a potential regulator of this upregulation of 
Slc38a4 during fasting.  In the liver, Foxa2 is negatively regulated by insulin.  
Insulin signaling stimulates a kinase cascade that leads to phosphorylation of a 
threonine residue of Foxa2, leading to Foxa2 nuclear exclusion.  Thus, during 
fasting, when insulin levels are low, Foxa2 is present in the nucleus and active; 
when insulin is present, Foxa2 is phosphorylated and shuttled out of the nucleus.  
This shuttling of Foxa2 does not occur in the pancreatic islets, where Foxa2 is not 
insulin-responsive.  Since Foxa2 is a transcriptional activator that is inhibited by 
insulin in the liver, but not in islet, we considered Foxa2 as a candidate regulator 
of Slc38a4, which we found to be upregulated in the liver during fasting, but not 
in pancreatic islets.   
 To study Foxa2 regulation, we used mice that were injected with either a 
GFP-expressing adenovirus, or an adenovirus that expresses a constitutively 
active form of Foxa2, which has the phophorylated Thr residue mutated to Ala.  
Through RT-PCR of a liver cDNA panel from overnight-fasted GFP-adenovirus- 
and Foxa2 (T156A)-adenovirus-infected C57Bl6 mice, we found upregulation of 
Slc38a4 with Foxa2.  We also looked for Foxa2 regulation of Slc38a4 expression in 
hyperinsulinemic and diabetic mouse models, transgenic mice overexpressing 
Srebp-1c in adipose tissue (Srebp-1c) and ob/ob mice, where Foxa2 is constutively 
inactive due to nuclear exclusion.  We found that infection of these mice with 
adenovirus expressing constitutively active Foxa2 at nuclear levels that are 
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similar to the fasted state led to even more pronounced upregulation of Slc38a4.  
In addition, we found that expression of both transcript isoforms of Slc38a4 are 
regulated by Foxa2 in all mouse models.  Thus, we have found that Foxa2 is a 
mediator of the insulin-responsive regulation of Slc38a4.   
 
5.6  Identification of Tcf1 and Foxa2 regulatory elements in the Slc38a4 “islet” isoform 
promoter 
 We wanted to determine the promoter elements responsible for Tcf1 and 
Foxa2 regulation.  We began by analyzing the Slc38a4 “islet” isoform promoter, 
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using the TFSEARCH program (ver.1.3).  This revealed a putative binding site 
for both Tcf1 and Foxa2 at position –70 in the “islet” isoform promoter.  In 
addition, when we compared this to the human SLC38A4 gene sequence, we 
found that this promoter element is conserved in both mouse and human (Figure 
26).   
 
 We generated luciferase reporter gene plasmids to investigate this 
putative binding site.  We found transactivation by both Tcf1 and Foxa2 when 
we co-transfected expression plasmids for these transcription factors along with 
a luciferase reporter gene plasmid with the Slc38a4 “islet” isoform promoter.  
The transcriptional activity of the luciferase reporter gene is reduced when the 




 In addition, we performed electrophoretic mobility shift assays to 
determine whether Tcf1 and Foxa2 bind directly to this site.  We generated 32P-
labeled double-stranded oligonucleotides containing the putative Tcf1/Foxa2 
binding site.  Incubating this probe with Hepa 1-6 (mouse liver cell line) extract, 
we were able to see specific radioactive band shifts corresponding to Tcf1 and 
Foxa2 binding (Figure 28).  Using cold oligonucleotides containing known Tcf1 
and Foxa2 sites, we were able to inhibit the radioactive band shifts in a specific 
manner, while a cold probe containing the mutated binding site was unable to 
inhibit the shift even at 100-fold excess.  The binding of both Tcf1 and Foxa2 to 
the site was further demonstrated by supershifting their respective bands using 
anti-Tcf1 and anti-Foxa2 antibodies.  An anti-c-jun antibody was also used as a 




5.7  Identification of Tcf1 and Foxa2 regulatory elements in the Slc38a4 “liver” isoform 
promoter 
 We performed a similar analysis of the Slc38a4 “liver” promoter to 
determine the promoter elements important for Tcf1 and Foxa2 regulation of this 
isoform.  Sequence analysis revealed two Tcf1 binding sites at positions –1000 
and –40 in the “liver” isoform promoter (Figure 29).  A Foxa2 binding site was 
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also identified in the promoter at position -220.  By comparing the mouse 
promoter sequence with the sequence upstream of the human SLC38A4 gene, we 
found that these elements are located in regions of sequence conservation 
between mouse and human.   
 
 We performed luciferase reporter gene assays with the Slc38a4 “liver” 
promoter, and compared levels of transactivation when we mutated the various 




 We found that mutating the putative Tcf1 binding site at position –1000 or 
–40 significantly decreases the level of transactivation by Tcf1 (Figure 30A).  
When we mutate both sites, we eliminate all transactivation by Tcf1.  We also 
found that mutating the Foxa2 binding site at position –220 also decreases the 
transactivation by Foxa2 in luciferase reporter gene assays (Figure 30B).   
 EMSA analysis was also performed using radioactively labeled 
oligonucleotides of all three of these putative binding sites in the Slc38a4 “liver” 
promoter, to determine whether Tcf1 or Foxa2 directly bind to these sites (Figure 
31).  We were able to see radioactive band shifts for the oligonucleotide probes 
for each site with the addition of Hepa 1-6 cell extract.  With the addition of anti-
Tcf1 and anti-Foxa2 antibodies, we were able to demonstrate that Tcf1 directly 
binds to the probe of the position –40 and –1000 Tcf1 binding sites, and that 
Foxa2 directly binds to the probe of the position –220 Foxa2 binding site.  We 
also found a strong band shift with the –1000 Tcf1 binding site, and found that 
this is due to direct binding by Foxa2 by supershifting this band with anti-Foxa2 
antibodies; however, through luciferase reporter gene assays, we found that this 
site is not important for Foxa2 transactivation, as mutation of the putative Foxa2 
site does not affect luciferase expression.  The specificity of the radioactive band 
shift by either Tcf1 or Foxa2 binding to the oligonucleotide probes was also 
demonstrated by the inhibition of this shift by the addition of cold probes 




5.8  Synergistic transactivation of Slc38a4 by Tcf1 and Foxa2 
 We were interested to see if Tcf1 and Foxa2 have a synergistic effect on 
transactivation of Slc38a4.  To determine this, we performed luciferase reporter 
gene assays, co-transfecting both Tcf1 and Foxa2 expression vectors with the 
reporter gene plasmids containing either the Slc38a4 “islet” or “liver” isoform 
promoters.  We found significantly higher transactivation through both the 
Slc38a4 “islet” and “liver” isoform promoters with Tcf1 and Foxa2, than we 
found by co-transfecting either factor singly with the promoter-reporter gene 
plasmids (Figure 32).  Thus, Tcf1 and Foxa2 are able to transactivate through 




5.9  In vivo binding of Foxa2 to the Slc38a4 promoters 
 We wanted to see whether Foxa2 binds to the Slc38a4 promoters in vivo.  
We performed chromatin immunoprecipitation analysis on liver tissue from 
C57Bl/6J and ob/ob mice infected with either Foxa2 (T156A)-adenovirus or GFP-
adenovirus.  Through chromatin immunoprecipitation with an anti-Foxa2 
antibody, we found that Foxa2 interacts with the promoters of both Slc38a4 
isoforms in fasted C57Bl/6J mice and the ob/ob mice infected with the Foxa2 
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(T156A)-adenovirus (Figure 33).  However, Foxa2 does not interact with these 
promoters in ob/ob mice infected with the GFP-adenovirus.  In addition, Foxo1, a 
related transcription factor, does not interact with either promoter in any of the 
conditions tested, as we are unable to amplify any of these promoter regions 
after chromatin immunoprecipitation with Foxo1.   
 
5.10  Expression of Foxa2 (T156A) increases arginine uptake by perfused mouse livers 
 Since we had shown Foxa2 regulation of an amino acid transporter gene, 
we wanted to demonstrate that Foxa2 activation does indeed lead to a change in 
amino acid uptake in vivo.  For this experiment, we infected C57Bl/6J mice with 
either adenovirus that expresses the constitutively active Foxa2 (T156A) or GFP-
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adenovirus as a control.  We perfused the liver of these mice with Krebs-
Henseleit buffer containing 3H-labeled arginine to assay the uptake of arginine 
by these livers.  We found significantly increased uptake of arginine by the livers 





CHAPTER 6 – DISCUSSION PART II 
 
6.1  Alternative splicing as a mechanism for differential regulation of Slc38a4 
 In this study, we examined the regulation of the Slc38a4 gene, which we 
had previously identified as being highly regulated by the transcription factor, 
Tcf1, in pancreatic islets.  We found that Slc38a4 was also regulated by Tcf1 in 
liver tissue as well; however, the level of regulation in the liver was less than that 
observed in the pancreatic islets.  We identified alternative transcriptional start 
sites leading to two transcript isoforms for Slc38a4.  While the liver expresses 
both Slc38a4 transcripts, islet tissue expresses only one transcript.  Furthermore, 
while both transcripts were found to be positively regulated by Tcf1, the “islet” 
transcript was more strongly upregulated by Tcf1.  We believe that these data 
together suggest that the differential expression of these two transcript isoforms 
and their differences in Tcf1 regulation may be the basis of the regulatory 
differences observed between the liver and islet expression of Slc38a4.    
 The existence of alternative transcripts for the Slc38a4 gene is interesting, 
however not entirely surprising.  Recent studies show that alternative splicing 
seems to be the rule for human genes rather than the exception, which explains 
how the number of human proteins outnumbers that of genes several-fold.  
Increasingly more studies have shown how alternative transcripts may also 
mediate tissue-specific regulation.  The regulation of Slc38a4 in the pancreatic 
beta-cell and in the liver that we have observed is such an example.  Yet another 
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example is the HNF4α gene.  HNF4α gene expression in pancreatic endocrine 
and exocrine cells is dependent on Tcf1, while HNF4α expression is not affected 
by the absence of Tcf1 in the liver.  Similar to our findings with Slc38a4, it was 
shown that HNF4α has two alternate tissue-specific promoters, one of which is 
mainly expressed in the islet and is highly regulated by Tcf1, while the other is 
expressed in the liver and is not affected by Tcf1 (Boj et al., 2001).   
 In addition to having distinct regulatory properties through the alternative 
promoters, the two Slc38a4 transcripts may have different functional properties 
conferred by their sequence differences.  The alternative transcripts of the Slc38a4 
gene that we have identified do not differ in sequence in their translated regions 
and encode proteins of identical sequence.  However, it is possible that these 
transcripts may still differ in their gene product activity through their sequence 
differences within the 5’-untranslated regions (UTR).  An intriguing example of 
activity regulation through the 5’-UTR is the Slc7a1 gene, which encodes the Cat1 
amino acid transporter.  It has been shown that the mRNA for the Slc7a1 gene 
contains an internal ribosome entry site (IRES) in its 5’-UTR (Fernandez et al., 
2001).  With amino acid starvation, general cap-dependent protein synthesis is 
inhibited (Pain, 1994); however, the IRES-mediated translation of the Slc7a1 
mRNA increases under conditions of amino acid starvation, providing a 
mechanism by which cells may preferentially translate only mRNAs that are 
essential for cell survival during periods of limited nutrient supply (Fernandez et 
al., 2001).   
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 It would be interesting to test the hypothesis that the 5’-UTRs of the two 
alternative transcripts of Slc38a4 may yield different translational properties.  For 
example, one may perform similar studies as Fernandez et al. (2001), and clone 
the two Slc38a4 5’-UTRs into bicistronic mRNA, where one reporter gene is 
translated through a cap-dependent scanning mechanism, while a second 
reporter gene encoded downstream of the 5’-UTR insert is translated only if it is 
preceded by an IRES.  Differences in 5’-UTR function may also be elucidated 
with cell lysate fractionation to purify polysomes and the transcripts associated 
with the polysomes.  One may then perform RT-PCR to determine the presence 
of either the “islet” or “liver” Slc38a4 transcripts to see if there is a difference in 
their association with the ribosomes.  These studies would elucidate potential 
differences in transcript interactions within the 5’-UTRs that may have 
translational consequences.   
 While increasingly more examples of alternative transcripts and promoters 
are being discovered to mediate tissue-specific expression and regulation, it is 
still unclear what mechanism causes a transcript to be predominantly expressed 
in one tissue rather than another.  Using the Slc38a4 gene as an example, the 
complete absence of the “liver” transcript in pancreatic islet tissue is a striking 
observation.  It would be interesting to study potential mechanisms for this 
phenomenon, particularly the possibility of differences in histone structure in the 
two different tissues.  This may be elucidated with additional chromatin 
immunoprecipitation assays with antibodies to acetylated histones and with 
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antibodies to un-acetylated histones to test for binding of the “islet” and “liver” 
promoter sequences in the two tissues.  It is possible that differences in histone 
structure and modification may be a general mechanism for tissue-specific 
transcript silencing.   
 
6.2  Regulation and function of Slc38a4 in the liver 
 In this study, we have also shown that Slc38a4 expression is upregulated 
in the liver of overnight fasted mice, and that this upregulation is inhibited by 
insulin.  Through in vitro and in vivo experiments, we have also demonstrated 
that Slc38a4 is a direct target of the transcription factor, Foxa2, as well as Tcf1.  
Furthermore, we have shown that Foxa2 overexpression in the liver can increase 
arginine uptake in liver perfusion studies, thus correlating the increase in Slc38a4 
gene expression with increase Slc38a4 transporter activity.   
 Our study is the first to identify an insulin-regulated transcription factor 
to regulate a member of the Slc38a family.  Previous work by Gu et al. (2005) had 
shown regulation of Slc38a3 to also be negatively regulated by insulin on a 
molecular level via the PI3-kinase pathway.  It is possible that Foxa2 may 
mediate the insulin-sensitive gene expression of Slc38a3, as well as other 
transporter genes.   
 We have found that both Tcf1 and Foxa2 regulate both alternative 
transcripts of Slc38a4, and that their transactivation is synergistic.  We also 
showed that Tcf1 expression does not change with fed or fasted states, while it 
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has been shown that Foxa2 activity is dependent on the absence of insulin 
signaling.  Our results suggest that while both transcription factors are important 
for Slc38a4 expression, they have distinct regulatory functions.  Tcf1 plays a role 
mainly in mediating basal expression levels of Slc38a4, while Foxa2 modulates 
Slc38a4 expression with changes in the metabolic state of the organism and 
insulin levels.   
 Foxa2 has already been shown to mediate other metabolic pathways in the 
liver, dependent on the metabolic state of the organism.  For example, it was 
demonstrated that Foxa2 mediates the increased hepatic fatty acid oxidation that 
occurs during fasting, which provides energy from fat stores for the organism 
while other energy sources are not available (Wolfrum et al., 2004).  We have 
now shown that Foxa2 may also mediate the liver response to fasting by 
increasing amino acid uptake, which may be broken down to carbon skeletons 
for the generation of glucose, as well as used for protein renewal.   
 In the ob/ob and Srebp-1c mouse models, Foxa2 is permanently excluded 
from the nucleus and inactive, due to the hyperinsulinemia (Wolfrum et al., 
2004).  In contrast, a related forkhead family transcription factor, Foxo1, shows 
resistance to insulin and may remain in the nucleus driving transcription of its 
target genes.  Foxo1 is normally responsible for increasing expression of genes 
involved in gluconeogenesis during fasting.  Thus, development of Foxo1 insulin 
resistance in hyperinsulinemic states results in exacerbation of hyperglycemia 
from inappropriate activation of the gluconeogenic pathways.  The insulin 
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sensitivity of Foxa2 in type 2 diabetic and hyperinsulinemic models may also 
contribute to the disease state: permanently inactive Foxa2 leads to decreased 
fatty acid oxidation, which leads to hepatic steatosis that may also increase 
insulin resistance.  However, in this study, we have shown another arm of Foxa2 
function that may help alleviate the type 2 diabetic state.  With hyperinsulinemia 
inactivating Foxa2, amino acid uptake will be lower, decreasing the amount of 
amino acid-derived substrates for gluconeogenesis.  Thus, Foxa2 nuclear 
exclusion in the type 2 diabetic and hyperinsulinemic models helps to decrease 
the gluconeogenesis that is being inappropriately driven by insulin-resistant 




CHAPTER 7 – EXPERIMENTAL PROCEDURES 
 
7.1  Experimental animals 
All animal models were housed in Laboratory of Animal Research Center 
(LARC), a pathogen-free animal facility at the Rockefeller University.  The 
animals were maintained on a 12-hour light/dark cycle and fed a standard 
rodent chow.  Genotyping of transgenic mice was performed on DNA isolated 
from three-week old mice by PCR (Lee et al., 1998).   
 
7.2  Cell culture 
MIN6 cells were cultured with DMEM medium containing 25mM glucose, 
15% fetal bovine serum, and 5μM 2-mercaptoethanol.  COS-7, Hepa 1-6, and 
HepG2 cells were cultured with DMEM medium containing 25mM glucose and 
10% fetal bovine serum.  Collagenized plates were used for culturing HepG2 
cells.  All cells were maintained in a humidified incubator at 5% CO2. 
 
7.3  In vitro radioactive ligand uptake assay 
MIN6 monolayers were plated at a concentration of 500,000 cells/well in 
six-well plates and assayed for arginine uptake the following day.  On the day of 
the assay, MIN6 monolayers were washed and pre-equilibrated in control 
Tyrode’s solution (135mM NaCl, 5mM KCl, 1.8mM CaCl2, 1mM MgCl2, 10mM 
Hepes, and 5.6mM glucose, pH 7.4) at 37ºC for 30-40 minutes.  To assay arginine 
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uptake, the cells were incubated with Tyrode’s solution containing 3H-arginine 
for a fixed amount of time.  Cells were then washed twice with ice-cold control 
Tyrode’s solution and lysed with RIPA buffer (50mM Tris, 1% NP-40, 0.25% Na-
deoxycholate, 150mM NaCl, 1mM EDTA, pH 7.4) for 20 minutes on ice.  Cell 
lysates were measured for 3H radioactivity content as well as protein content for 
normalization.  For ion dependence experiments, the Tyrode’s buffer used for 
uptake assays was made substituting either Na with choline, or Cl with 
gluconate.  For the uptake experiments, all incubations and washes were timed 
to the second.   
 Assays for the mNAT3 protein transport activity were performed in COS-7 
cells.  COS-7 cells were transfected using Fugene 6 at 50% confluency in six-well 
plates with either mNAT3 expression vector or with pcDNA3.1 (Invitrogen) as a 
control empty vector.  Radioactive ligand uptake assays were performed two 
days post-transfection.  Uptake assays were performed as described for MIN6. 
 
7.4  Pancreatic islet isolation 
Pancreatic islets were isolate from 6 to 8-week old mice.  The mouse 
pancreas was first perfused with Hank’s Buffered Salt Solution (HBSS) through 
the bile duct.  Perfused pancreata were dissected out and placed in a solution of 
HBSS containing 1-1.5mg/mL collagenase, type XI (Sigma) and digested at 37ºC 
for 10-12 minutes.  Digested pancreata were washed two times with HBSS.  The 
tissue was then applied to a Ficoll gradient (25%, 23%, 20.5%, and 11% layers) 
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and centrifuged at 800 x g for 10 minutes.  Islet tissue at the interface between the 
23% and 20.5% layers was taken and washed once with HBSS before being 
resuspended in culture medium.  Islets were cultured overnight in RPMI 
medium containing 11.1mM glucose and 10% fetal bovine serum.  Total RNA 
was extracted from picked islets using TRIzol reagent (Gibco-BRL).   
 For experiments examining gene expression in the islets during fasting 
and fed states, pancreatic islets were isolated as above.  However, islets were 
resuspended in cold HBSS following the final HBSS wash, and never cultured in 
the RPMI medium.  Islets were then picked directly from the HBSS suspension 
and used immediately for RNA extraction with TRIzol.   
 
7.5  Gene expression array analysis 
 RNA was pooled from 20 Tcf1 +/+ and 30 Tcf1 -/- mice.  A small aliquot 
of each sample was analyzed on a denaturing formaldehyde gel to assess RNA 
sample integrity.  RNA was purified using RNeasy columns (Qiagen), and then 
used for cDNA synthesis using the Superscript Choice cDNA Synthesis Protocol 
(GibcoBRL), except that an HPLC-purified T7-Promoter-dT24 primer (Genset) 
was used to initiate the first-strand reaction.  Biotin-labeled cRNA was 
synthesized from T7-cDNA using the RNA transcript labeling kit Bio Array 
(Enzo), supplemented with biotin 11-CTP and biotin-16-UTP (Enzo) as specified 
in the Affymetrix technical manual.  The sample was cleaned with RNeasy 
columns (Qiagen) to remove free nucleotides and quantitated 
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spectrophotometrically.  Biotin-labeled cRNA was fragmented in 40mM Tris (pH 
8.0), 100mM KOAc, and 30mM MgOAc for 30 minutes at 94°C.  Hybridization 
samples were prepared according to the Affymetrix manual with a final 
concentration of fragmented cRNA of 0.05μg/μL. 
 Affymetrix Genechip MG-U74A, MG-U74B, and MG-U74C probe arrays 
were prehybridized with 100mM MES (Sigma) pH 6.6, 1M[Na+], 20mM EDTA, 
and 0.01% Tween-20 (Sigma) for 10 minutes at 45°C.  Hybridization samples 
were heated to 99 C for 5 minutes, equilibrated to 45 C for 5 minutes, and 
centrifuged at 14,000 x g for 5 minutes to sediment any particulate matter.  The 
prehybridization solution was removed and the sample was added to the probe 
array and allowed to hybridize for 16 hours, rotating at 60 rpm at 45 C.  Probe 
arrays were subsequently washed and stained according to the Affymetrix 
technical manual in an Affymetrix fluidics station.  The arrays were scanned 
using a Hewlett-Packard confocal laser scanner and visualized using Affymetrix 
Genechip 3.1 software.  Comparison of gene expression levels between the 
different groups were carried out using software Microarray Suite 4.0. 
 
7.6  RNA interference 
 Synthetic siRNAs were synthesized by Proligo.  Sequences were designed 
to target Slc38a4 and Slc7a3.  The sequences targeting Slc7a3 are: siRNA1 5’-
GUAUUGUGAUCUCGAUGUUTT-3’, and siRNA2 5’-GCGUUCUCAUCCUCA 
GAUATT-3’.  The sequences targeting Slc38a4 are: siRNA1 5’-GAUGCCGAAA 
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GUCAGAAGUTT-3’, and siRNA2 5’-CCAUCUACAGCGAGCUUAATT-3’.  
siRNAs were transfected into MIN6 cells by electroporation using the 
Nucleofector Kit V (Amaxa), according to the manufacturer’s protocol.  For 
electroporation into 3-5x106 cells, 0.5 nmoles of siRNA was used. 
 
7.7  Protein immunoblotting 
 We prepared cell extracts for immunoblotting by lysing in RIPA buffer for 
20 minutes on ice, and centrifuging at 13,000 x g to remove debris.  Samples were 
loaded onto SDS-glycine 4-15% polyacrylamide gradient gels (Biorad) and 
transferred onto a nitrocellulose membrane (Schleicher & Schuell) by 
electroblotting.  Membranes were first incubated with TBS with 0.1% Tween 20 
(Sigma) and 5% milk for one hour at room temperature.  Membranes were then 
incubated with primary antibodies overnight at 4°C.  The antibody to mNAT3, 
the Slc38a4 gene product, (a generous gift from Dr. J. X. Jiang, Department of 
Biochemistry, University of Texas Health Science Center) was used at a 
concentration of 1:3000.  We used anti-gamma-tubulin antibody (Sigma) as a 
loading control at a concentration of 1:10,000.  Membranes were then washed 
three times for five minutes each with TBS with 0.1% Tween 20 (TBST) before 
incubating with TBST with 5% milk and either anti-mouse (for gamma-tubulin 
detection) or anti-rabbit (for Slc38a4 protein detection) HRP-conjugated 
antibodies (Calbiochem).   
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7.8  In vitro insulin secretion and measurement 
MIN6 cells were washed once and preincubated for 30 minutes in Krebs 
Ringer Buffer (KRB; 135mM NaCl, 1.5mM CaCl2, 0.5mM KH2PO4, 3.6mM KCl, 
0.5mM MgSO4, 2mM NaHCO3, 10mM Hepes, 0.1% BSA, pH 7.38) containing 
2.5mM glucose.  Cells were then washed once and incubated for one hour with 
KRB containing 3.3mM glucose for basal insulin secretion measurements, 3.3mM 
glucose plus 20mM arginine or leucine, or 25mM glucose for stimulated insulin 
secretion measurements.  Insulin secretion assay samples were taken from each 
well following the incubation and centrifuged for five minutes at 400 x g to pellet 
any loose cells in the sample.  The supernatant was carefully taken off and 
measured for insulin content using an insulin radioimmunoassay kit (Linco 
Research).   
 
7.9  Vectors 
The mNAT3 expression vector was generated by cloning the cDNA for 
Slc38a4 (Genbank accession no. BC024123) into the pcDNA3.1 vector 
(Invitrogen).  The reporter plasmid Islet/luc-wt was generated by first 
performing PCR to amplify a 600-bp fragment of the promoter for the Slc38a4 
“islet” isoform (Genbank accession no. AY027919), using primers with the 
sequences TGCTCACTATGTTCTTAGCAGGTG and GGGTCTTTTAAGCTGA 
TTGCACGCC.  The amplified fragment was cloned into the vector, pCR®II-
TOPO using the TOPO TA cloning kit from Invitrogen, according to the 
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manufacturer’s instructions.  Plasmids with the promoter fragment in a forward 
orientation were selected after sequencing.  The insert was then cut out of the 
pCR®II-TOPO vector with the restriction enzymes Kpn I and Xho I and ligated 
into the pGL2-Enhancer vector (Promega) cut with the same enzymes.   
The reporter gene plasmid Islet/luc-mut is identical to Islet/luc-wt, except 
that the sequence at position –74 to –65 has been mutated from AATAATTTAC 
to GTGTATCTCT.  The reporter plasmid Liver/luc-wt was generated by first 
performing PCR to amplify a 1200-bp fragment of the promoter for the Slc38a4 
“liver” isoform (Genbank accession no. BC024123), using primers with the 
sequences GAAAGATGACAATTAAGCAGCCAA and CTGAACTTTTTGGAA 
AGCAAGACA.  The amplified fragment was cloned into the pCR®II-TOPO 
vector using the TOPO TA cloning kit from Invitrogen.  The insert was then cut 
out of the pCR®II-TOPO vector with the restriction enzymes Kpn I and Xho I and 
ligated into the pGL2-Enhancer vector (Promega) cut with the same enzymes.  
The reporter gene plasmids with mutated Tcf1 binding sites in the “liver” 
promoter are identical to Liver/luc-wt except that Liver/luc-1000M has the 
sequence from -1000 to -992 changed from TTAATAAAT to CCAATAAGG, 
Liver/luc-40M has the sequence from -45 to -42 changed from ATTG to CGCG, 
and Liver/luc-40,1000M has both of the previously described sequence 
exchanges.  The reporter gene plasmids with mutated Foxa2 binding sites in the 
“liver promoter” are also identical to Liver/luc-wt except that Liver/luc-220M 
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has the sequence from –225 to –209 changed from AAAGCCAAAATTCCAAA to 
CCAGCCACCATTCCACC. 
 
7.10  Transient transfections and luciferase assay 
Fugene 6 reagent (Roche) was used to transfect HepG2 cells, according to 
the manufacturer’s directions.  The total transfected DNA amount per well in a 
six-well plate was 0.5μg, using equal amounts of the luciferase reporter 
construct, transcription factor expression vector, and CMV-LacZ plasmid.  
Luciferase activity was measured two days following transfection and was 
normalized for transfection efficiency, assayed by β-galactosidase activity (Shih 
et al., 2001). 
 
7.11  Whole cell extract preparation for electrophoretic mobility shift assays 
HepG2 cells were grown to confluency in 150mm tissue culture dishes.  
Cells were washed once with ice-cold PBS and scraped into 3mL PBS.  Cells were 
centrifuged at 4,000 x g for four minutes and resuspended in two volumes of 
high-salt extraction buffer consisting of 400mM KCl, 20mM Tris pH 7.5, 20% 
glycerol, 2mM DTT, 1x Complete TM Protease Inhibitors (Boehringer 
Mannheim), and 20ug/mL aprotinin (Sigma).  Cell lysis was performed by 
freezing and thawing.  Cellular debris was removed by centrifugation at 15,000 x 
g for ten minutes at 4ºC.  Whole cell extracts were stored at -80ºC.   
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7.12  Electrophoretic mobility shift assay (EMSA) 
EMSA analysis was performed as described previously (Shih et al., 2001) 
with minor modifications.  Each assay contained 10μg of whole cell extracts and 
2μg poly-dIdC (Sigma), sonicated to be 200-400 basepairs in length, in binding 
buffer (20mM Hepes pH 7.9, 10% glycerol, 150mM NaCl, 1mM DTT).  Whole 
cells extracts were incubated with 32P-labeled double-stranded oligonucleotide 
probes containing the wild-type or mutant Tcf1 or Foxa2 binding sites in Slc38a4 
promoters.  For the Slc38a4 islet promoter Tcf1/Foxa2 binding site, probe 
sequences were: WT 5’-TCTTCCTTTGTCAATAATTTACTTTTGT, and Mut 5’- 
TCTTCCTTTGTCGTGTATCTCTTTTTGT-3’.  For the Slc38a4 liver promoter Tcf1 
binding sites, probe sequences were: -1000 WT 5’-ATCTCAGAGTTAATAAA 
TCAAATGGGCACAA-3’, -1000 Mut 5’-ATCTCAGAGCCAATAAGGCAAATG 
GGCACAA-3’, -40 WT 5’-GGTCTTTAAATCATTGTCTTGCTTTCCA-3’, and –40 
Mut 5’-GGTCTTTAAATCCGCGTCTTGCTTTCCA-3’.  For the Slc38a4 “liver” 
promoter Foxa2 binding sites, probe sequences were: -220 WT 5’- 
GCCAAAATTCCAAAAGCAAATAGAAATT-3’, and -220 Mut 5’- GCCACCA 
TTCCACCAGCAAATAGAAATT-3’.  The cold competitor for Tcf1 binding was 
an unlabeled double-stranded oligonucleotide containing the Tcf1 binding site in 
the TMEM27 promoter (sequence: 5’-GGAGATTTTCGTAAATAACTGACA-3’; 
Akpinar et al., 2005).  The cold competitor for Foxa2 binding was an unlabeled 
double-stranded oligonucleotide containing the Foxa2 consensus site (sequence: 
5’-GTTGACTAAGTCAATAATCAGAATCAG-3’).  Supershifts were carried out 
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with an anti-Tcf1 antibody (Geneka Biotechnology Inc.) or an anti-Foxa2 
antibody (generous gift from Dr. J. E. Darnell).  As a control, anti-c-jun antibody 
was used (Santa Cruz Biotechnology).   
For each reaction, 10μg whole cell extract was first incubated at room 
temperature for ten minutes in binding buffer with 2μg poly-dIdC.  Cold 
inhibitors and antibodies were then added to the reactions, and all samples were 
incubated for another five minutes at room temperature.  Radioactive probes 
were finally added to each reaction, and the samples were incubated for another 
15 minutes at room temperatures.  Samples were then loaded onto a 4% 
polyacrylamide gel (0.25X TBE) and run at 200-250V.   
 
7.13  Chromatin immunoprecipitation 
 Chromatin immunoprecipitation was performed on liver tissue from 
C57Bl/6J mice and ob/ob mice that had been infected with either Foxa2 (T156A)-
adenovirus or GFP-adenovirus (1011) via tail vein injection ten days prior to the 
experiment.  Liver tissue was homogenized in phosphate-buffered saline (PBS; 
Sigma) containing 1x Complete TM Protease Inhibitors (Boehringer Mannheim), 
and cross-linked with 1% formaldehyde for ten minutes at room temperature.  
Cross-linking was stopped with the addition of glycine to a final concentration of 
0.125M.  Cells were washed twice with PBS containing protease inhibitors.  The 
Chromatin Immunoprecipitation Assay Kit from Upstate Cell Signaling 
Solutions (Lake Placid, NY) was used for the rest of the procedure, according to 
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the manufacturer’s instructions.  Anti-Foxa2 antibody and anti-Foxo1 antibody 
(Cell Signaling) were used for immunoprecipitation.  Primers were used to 
amplify the Slc38a4 “islet” promoter region from –180 to –1, and the Slc38a4 
“liver” promoter region from –230 to –1.   
 
7.14  Liver perfusion and radioactive ligand uptake assay 
 Mice were infected with either Foxa2 (T156A)-adenovirus or GFP-
adenovirus (1011 particles per mouse) ten days before the perfusion experiment.  
Mice were fasted overnight, and anesthetized with intraperitoneal injection of 
pentobarbitone sodium (60mg/kg body weight).  The portal vein and the inferior 
vena cava were cannulated.  The liver was perfused with Krebs-Henseleit (KH) 
buffer (119 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2mM MgSO4, 1.2mM 
KH2PO4, 25mM NaHCO3, 5mM glucose) with 20ng/mL insulin, equilibrated 
with 95% O2/5% CO2.  The rate of perfusion was maintained at 1 mL/minute.  
Once blood was flushed out of the liver with KH buffer, we began a timed 
perfusion with KH buffer with 20ng/mL insulin and 300uM arginine labeled 
with 3H.  The outflow was collected and radioactivity levels were measured.  
Uptake was measured by subtracting the CPM from the outflow from the input 
perfusion buffer CPM.  Cumulative uptake was normalized by the radioactivity 
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